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Abstract 
 
 Alpha-1-acid glycoprotein (AGP) is a 43kDa glycoprotein, so called due to the 
post-translational addition of carbohydrate units to the main protein. AGP is the second 
most abundant protein found within the serum of humans at normal physiological 
conditions, and is a positive acute phase protein produced by hepatocytes within the 
liver. As AGP is a positive acute phase protein, the concentration of AGP has been 
found to increase when a person is experiencing an acute phase response (APR); this 
is the body’s first line of defence against stressful stimuli, such as bacterial and viral 
infections, strenuous exercise, and physical injury.    
 As a result of the APR, it has been found that the structure of the carbohydrate 
units attached to the protein backbone can be altered. During a normal physiological 
state, 12-20 glycoforms of AGP can exist, however, this number can increase during 
the APR. A single molecule possesses five branching sites along the protein backbone, 
where the monosaccharide units bond to the AGP molecule in the form of branches; 
these branches can either be bi, tri, or tetra-sialylated arrangements.  It is this attribute 
of AGP that is the focus of this research within this project. Previous studies have 
shown that the altered glycosylation of AGP has the potential to differentiate between 
different types of liver diseases and breast cancers. While it has been shown that the 
APR can be induced by physical injury, no studies have been carried out to determine 
whether or not a physical injury induced APR can alter the glycosylation patterns of 
AGP. 
 Physical injury samples for the project were collected via venepuncture from 
volunteers who were injured while taking part in the sport of downhill mountain biking; a 
sport chosen due to it’s inherent dangers and the potential for injury. A two fold 
analysis of these samples was then carried out, by analysing the monosaccharide 
composition of the physical injury samples, before analysing the oligosaccharide 
structure of these samples, both being achieved through high pH anion exchange 
chromatography. The collected injury samples were then compared against collected 
normal blood samples, healed samples from previously injured volunteers while one 
sample remained unknown for the duration of the project.  
 Of the collected samples, it was seen that physical injury does have an effect 
on the glycosylation patterns of AGP. Furthermore, it was seen throughout the study 
that different injury types can produce different effects on the glycosylation patterns of 
AGP. Finally, the diagnostic potential of AGP was explored by comparing the 
monosaccharide and oligosaccharide compositions of the unknown injury sample 
against the compositions of the known injury samples. Once comparisons had been 
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completed, it was found that the unknown shared a great deal of homology with known 
fracture injuries, before the unknown was confirmed as a fracture injury itself.  
 In conclusion, the aim of the project was to determine whether or not physical 
injury induced APR can affect the glycosylation patterns of AGP. This project has 
confirmed that physical injuries can affect the glycosylation patterns of AGP. Further 
research within this area can then be carried out, such as studying the changes in 
glycosylation patterns throughout the recovery process. 
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1.1 Alpha-1-Acid Glycoprotein 
1.1.1 Discovery of AGP 
 Alpha-1-Acid Glycoprotein (AGP, also known as Orosomucoid) was first 
discovered in 1950 by Schmid and colleagues (Schmid, 1950). AGP is a 43kDa 
glycoprotein so called due to the 45% of post-translationally added 
carbohydrate units to the molecule (Schmid et al., 1977). At the time of its 
discovery, AGP was thought to possess the largest amount of post-
translationally added carbohydrate in the form of oligosaccharide chains (glycan 
chains) within the human body; this would later be refuted with the discovery of 
galactoglycoprotein of which possessed the post-translational addition of 
carbohydrate equating to 76% of it’s total molecular weight (Schmid et al., 
1980). AGP is still the second most abundant protein within the serum of 
humans, with only albumin present more within the body at normal physiological 
conditions (Gallacher, 2009). The majority of AGP within the body is produced 
by the hepatocytes within the liver, however, centralised production of AGP 
within other organs has been noted (although not to the same concentration as 
within the liver), such as within the prostate and granulocytes (Poland et al., 
2002).  
 
1.1.2 The Acute Phase Response 
 The Acute Phase Response (APR) is one of the body’s first line of 
defence against trauma, pathogens and other harmful stimuli. Specifically, the 
APR can be activated through bacterial and viral infections, such as leprosy 
(Gupta et al., 2010), disease, diabetes (Poland et al., 2001), childbirth (Smith et 
al., 2002), the first few days of life (Kushner, 1982), strenuous exercise, and, 
importantly within this project, physical injury (Kushner and Rzewnicki, 1994). 
The APR begins minutes after the introduction of the stressful stimuli, and will 
continue for 1-2 days after the event (Kushner, 1982). AGP is a Positive Acute 
Phase Protein (PAPP), meaning that the serum level of AGP increases after the 
initiation of the APR (Clementson, 1997). AGP’s typical concentration within the 
blood out with this event is that of 0.5-1mg/ml (Kremer et al., 1988), however, 
during the APR the concentration of AGP can increase between two and ten 
times (Petersen, et al., 2004). The production of AGP during this event is 
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controlled by interleukins 1 and 6 (IL-1 and IL-6) and glucocorticoids (Baumann 
et al., 1989). Increases in AGP have been reported in diseases such as cancer 
and rheumatoid arthritis (van Dijk, 1995), during periods of stress, pregnancy 
and heart attacks (Duche et al., 2000), although the exact function of the 
glycoprotein remains unknown. 
 The APR begins with the introduction of the harmful stimuli (for example, 
a pin to the thumb); immediately, pain is felt within the individual, and 
stimulation of the endothelial cells, fibroblasts and macrophages within the 
thumb begins. This in turn leads to the stimulation of IL-1, IL-6 and tumour 
necrosis factor Alpha (TNFα); the response of this then feeds back to the 
stimulation of the endothelial cells, fibroblasts and macrophages at the site of 
injury (Goldsby et al., fifth edition). The production of IL-1, IL-6 and TNFα then 
leads to the increase in secondary systemic effects within the individual; this 
includes fever (to inhibit the growth of a pathogen), loss of appetite, an increase 
in tiredness, an increase in white blood cell production (leukocytosis), and an 
increase in glucose production for use as energy (gluconeogenesis) to aid in the 
healing process (Goldsby et al., fifth edition). The increase in IL-1, IL-6 and 
TNFα also leads to the alteration in the acute phase proteins (APPs) within the 
serum of the individual; this includes the increased presence of AGP within the 
blood (due to it’s status as a PAPP), while also leading to a decrease in the 
serum concentration of negative acute phase proteins (NAPP), such as 
albumin. Following this, the body then increases the level of fluid, called 
exudate, leading to swelling in the affected area, called edema, which begins to 
isolate the stimuli and prevent it from spreading to other parts of the body 
(Goldsby et al., fifth edition); typically, this is process is categorised 
physiologically as a redness, pain and swelling due to increased vascular 
permeability (possibly due to the effects of AGP) around the area of stimulation 
(Haraldson and Rippe, 1987). The healing process itself can therefore begin. 
The APR associated increase in AGP remains at an increased level for 1-2 
days after the initial introduction of the stimulus (Kushner, 1982). In addition to 
the increased production of serum AGP, however, there is also an alteration in 
the glycan chain arrangements along the polypeptide backbone of the AGP 
molecule (Ceciliani and Pocacqua, 2007); i.e. there will be an appearance of 
new types of chains that would not be expected in the AGP molecule, like an 
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increased appearance in tetra-antennary chains, or a decrease in bi-antennary 
chains when compared to resting levels. 
 
1.1.3 Structure of AGP 
 As previously mentioned, most of the serum AGP within the body is 
produced within the liver. The production of the protein is coded by three genes 
on chromosome 9 of the human genome; AGP-A, AGP-B and AGP-B’. AGP-A 
codes for the ORM1 variant of the protein (Dente et al., 1987), while AGP-B and 
AGP-B’ (two identical genes) code for the ORM2 variant of the protein (Tomei et 
al., 1989). AGP-A, however, produces the majority of the AGP within the liver, 
100 times more so than the other two genes (Dente et al., 1987). The ORM2 
variant of AGP differs from the ORM1 variant of AGP in 22 bases.  
 The protein molecule of AGP is 183 bases long. Within this protein, there 
are five bonding sites, present on the amino acid asparagine (Asn), with which 
carbohydrate units can attach to the protein molecule within their glycan chains. 
It is within these N-linked bonding sites, that the variations within the molecule 
are introduced. Figure 1. shows a typical monosaccharide make up and 
arrangement of glycan chains on the protein backbone of the AGP molecule; 
this diagram also shows the three possible arrangements that each glycan 
chain can take, a bi-antennary chain (two branches), a tri-antennary chain 
(three branches) and a tetra-antennary chain (four branches). Each glycan 
chain is bound to one of these five sites, (positions -15, -38, -54, -75, -85). In a 
normal physiological state, only 10-20 glycoforms of an AGP exist due to the 
specific combinations of chains of which can appear on the Asn sites, however, 
during the APR, this number can increase further; theoretically, more than 105 
glycoforms of AGP can exist (Cecliani and Pocaqua, 2007). Evidence has also 
been gathered to suggest that tissue specific AGP could also possess it’s own 
modifications based on it’s tissue of origin, i.e. AGP produced in the 
granulocytes have been found to possess a higher molecular weight than 
plasma AGP (50-60kDa as opposed to 43kDa), this is thought to be due to the 
strongly fucosylated and sialylated polylactosamine units that make up the 
carbohydrate additions to the molecule (Poland et al., 2005). 
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Figure 1. AGP Glycan Chain Diagram  
       Glucosamine     Mannose        Galactose    Fucose        Neuraminic Acid 
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 In addition to the protein backbone of the AGP molecule, each AGP 
molecule is made up of glycan chains, these form the carbohydrate portion of 
the molecule. Each glycan chain is made up of monosaccharide molecules, 
bonded together by glycosidic bonds. The actual monosaccharides of which can 
appear within the glycan chain are typically mannose, galactose and 
glucosamine; with some chains being terminated by either the monosaccharide 
fucose, or neuraminic acid. These molecules are then arranged into glycan 
chains like those seen in Figure 1. 
 The glycan chains are bound to the molecule through a process called 
glycosylation; this is the post-translational addition of carbohydrate units to a 
protein molecule. This process, literally, makes AGP a glycoprotein. A glycan 
chain is bound to the protein backbone at one of the five bonding sites stated 
above. However, there is a degree of specificity within the AGP molecule as to 
what type of branch can bond to a particular bonding site; tetra-antennary 
chains cannot bind at site one, site two cannot bond chains with a high 
presence of the monosaccharide fucose, bi-antennary branches cannot bind to 
site 4, and chains with a high presence of fucose within them can be found on 
sites 4 and 5 of the protein backbone. 
 AGP possesses a low isoelectric point (pI) between 2.8-3.8 (Mondal et 
al., 2009), this is believed to be due to the presence of neuraminic acid as a 
common terminating sugar on each of the glycan chains and accounts for  10-
12% of the carbohydrate moiety of the overall AGP molecule (Fournier et al., 
2000). Fucose can be another terminating sugar on the glycan chains, however, 
Fournier et al., (2000) states that 30% of human plasma does not contain any 
fucose, and that a high degree of fucosylation is suggestive of a low presence 
or absence of bi-sialylated branches, and an increased presence of tri- and 
tetra-sialylated branches (Fournier et al., 2000). The structure of the AGP 
protein has been shown to contain 15% α-helices, 41% β-sheets, 12% β-turns, 
and 24% of unordered structure (Ceciliani and Pocaqua, 2007), which has lead 
to the belief that AGP belongs to a sub-family of lipocalins called the 
immunocalins, due their similar structures. 
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1.1.4 AGP Function 
 The exact function of AGP remains unknown at this point in time. 
Numerous studies have taken place to determine the function of AGP, however, 
there is still disagreement. It is fully possible that AGP is exactly what these 
studies have shown; a PAPP, that acts as a transportation molecule, an 
inhibitor of microbial function, that can regulate the body’s immune response to 
a degree by increasing vascular permeability (Haraldsson and Rippe, 1987), 
and a binder of basic drugs (Hochepied et al., 2003) such as methadone 
(Behan, 2010) and steroids if need be.  
Due to the increased presence of AGP within the human body during the 
APR, AGP is thought to be involved within this process. The structure of AGP is 
similar to that of the immunocalins; this is a family of proteins of which are able 
to exert immunomodulatory effects on the human body, and help to regulate the 
body’s immune system (Logdberg and Wester, 2000). Due to the structure of 
the glycoprotein being mostly β-Sheets, AGP is thought to be involved within 
the APR as a transport protein (Ceciliani and Pocaqua, 2007). This theory can 
also be taken further, as AGP has been shown to bind basic drugs (Ceiliani and 
Pocaqua, 2007); this is thought to be achievable due to the low pI of the 
molecule. However, AGP has also been shown to bind neutral drugs and 
steroid hormones as well (Israeli and Dayton, 2001). AGP has also been shown 
to bind toxic molecules from micro-organisms (Ceciliani and Pocacqua, 2007), 
further strengthening the theory that AGP is a transport molecule during the 
APR. 
 Furthermore, there is a possibility that AGP may encourage vascular 
permeability within the APR (Fournier, 2000). This supports the theory that AGP 
may be involved within this process as there is an increase in vascular 
permeability within the area of injury leading to an increase in swelling and 
heat/redness around the affected area in question.  
 However, it should also be stated that as there is an increase in the level 
of AGP within the serum during numerous different conditions; the rise in AGP 
is itself not diagnostic of a disease or other physiological state. There are 
numerous different states that could affect the level of AGP, thus, it would not 
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be reliable to use this rise as a biomarker. It is the change in glycosylation 
pattern that could act as a potential biomarker for a physiological state.  
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1.2 Glycosylation Patterns of AGP 
1.2.1 The Production of Glycosylation Patterns 
 The glycosylation pattern of AGP is the post translationally added 
monosaccharide units to the protein backbone of the AGP protein, making AGP 
a glycoprotein. The glycosylation pattern is then determined by the 
arrangements of these monosaccharides as oligosaccharide structures, also 
known as branches.  As previously stated, there are three genes which produce 
AGP; AGP-A, AGP-B and AGP-B’. While the AGP-A variant is produced in 
greater quantities than AGP-B/B’ (Dente et al., 1987), it was found that the 
concentrations of each variant of AGP would increase during the APR, and that 
the glycosylation of each of these variants is not dependant on their genetic 
expression (van Dijk et al., 1991).  
 Glycosylation is a complex process driven forward by enzyme 
catalysation. The process of glycosylation typically occurs in two stages; the 
synthetic pathway (the production of the necessary glycan chains) takes place 
within the cytosol and the endoplasmic reticulum (ER), and the processing 
pathway (the quality checking of the glycan chains) taking place within the ER 
and the golgi apparatus. Each glycan chain is made up of monosaccharide 
units, these mono units are converted into high sugar nucleotides (such as 
uridine diphosphate (UDP)- GlcNAc and guanine diphosphate (GDP)-mannose) 
and are transferred to membrane bound lipid dolichylphosphate (Dol-P) on the 
cytosolic side of the ER to form Man5GlcNAc2-Dol-P. GlcNAc-1-
phosphotransferase, GlcNAc-transferase and mannosyltransferases are then 
required to catalyse the transfer from their donor sugar nucleotide to the Dol-P. 
This donor sugar nucleotide then translocates to the luminal side of the ER, 
through the use of a flippase. A further seven monos are then donated in this 
way, binding together through glycosidic bonds to produce the fourteen 
Glc3Mann9(GlcNAc)2 oligosaccharide precursor.  
 After the production of the oligosaccharide precursor, synthesis of 
glycosylation patterns occurs in four stages, this is summarised in Figure 2. 
below;  
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Figure 2. Glycosylation Pathway Diagram 
 Initially, stage 1 is the transfer of the precursor from Dol-P donor to 
nascent glycoproteins occurs within the rough endoplasmic reticulum 
(RER); this process requires a multimeric oligosaccharyltransferase 
complex. 
 Stage 2 then involves glycosidases trimming the precursor while being 
transported from the RER to the golgi. 
 Stage 3 involves the substitution of the precursor, which takes place 
within the medial golgi by GlcNAc-transferases. 
 Finally stage 4 of glycosylation pattern production involves the elongation 
of the precursor which takes place within the trans-golgi network, 
resulting in the addition of glycan chains to the protein backbone. 
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Furthermore, the protein structure of β-sheets and loops are formed through 
the bonding between the anomeric –OH group of the terminal monosaccharide 
(GlcNAc) and the –NH group of the Asn residue. However, possible interactions 
may occur between N-linked glycan chains and aromatic, uncharged amino acid 
side chains within the three amino acids on either side of the glycosylated Asn 
residue. The glycans attached to the Asn are then exposed to the competitive 
action of glycosidases (which catalyse the “trimming” of the glycan chains), 
such as glucosidase and mannosidase, and glycosyltransferases (which 
catalyse the addition of the monosaccharide donors to the donor protein). It is 
this competition between enzymes for substrates that increases the diversity 
within the microheterogeneity. 
 
There are several regulatory steps in place to prevent the synthesis of 
incorrect glycoproteins within the body; upon trimming of two glucose molecules 
by α1,2-glucosidase I and α1,3-glucosidase II within the ER, the nascent 
glycoproteins then enter the calnexin/calreticulin cycle which ensures only 
correct folded proteins can continue within the pathway. If the folding is 
incorrect, a luminal glycosyltransferase adds a glucose residue onto the 
misfolded protein, forcing it to re-enter the calnexin/calreticulin cycle. This 
process would be repeated until the protein is correctly folded and any 
remaining glucose is removed by glucosidase II.  
 
1.2.2 The Effect of the APR on Glycosylation Patterns 
 It has been seen previously, that the APR can produce an increase in the 
level of AGP when the body is experiencing a stressful stimuli (Kremer et al., 
1988); however, not only can the APR affect the concentration of AGP within 
the body, it can also affect the types of monosaccharides and the arrangements 
of these monosaccharides as glycan chains; these are the glycosylation 
patterns. As mentioned previously, when the body is physiologically “healthy”, 
only 12-20 glycoforms of AGP exist within the body. It has been noted in 
previous studies however, that during the APR, an increased number of 
glycoforms can exist and appear within an individual. Within human AGP, three 
types of glycan branching are of interest within this study. These are bi-
11 
 
antennary branching (a chain ending in two branches), tri-antennary branching 
(chain ending in three branches) and tetra-antennary branching (chain ending in 
four branches). The increased presence of tri and tetra branching is indicative of 
more complex branching types within the AGP molecule. An increased 
presence of fucose monosaccharide units may also be indicative of tri and tetra-
antennary chains within the AGP molecule (Fournier et al., 2000), however, 
evidence from Higai et al., (2005) has since found the degree of branching and 
the degree of fucosylation to be independent of each other, i.e. samples were 
found to contain an increased number of bi-sialylated glycans (indicative of 
decreasing glycan complexity) with an increased level of fucosylation (a 
possible indicator of branch complexity). It’s been found that glycosylation 
patterns exhibit decreased branching during acute inflammation (Brinkmann-
van der Linden et al., 1996), while chronic inflammation states, such as 
rheumatoid arthritis, have been found to exhibit increased branching patterns 
(De Graaf et al., 1993) and an increase in fucosylation (Pawlowski et al., 1989). 
This evidence is further supported by Higai et al., (2005), who found increased 
instances of bi-sialylated glycans within the sera of patients suffering from acute 
inflammation, however, increases in fucosylation were also found within these 
samples; conversely, chronic inflammation sufferers were found to possess 
increased fucosylation within their tri- and tetra-sialylated glycans. It has been 
found by Fujimura et al., (2008) that there was also an increase in fucosylation 
in glycans obtained from those suffering from prostate cancer.  
Furthermore, it has also been seen previously, that the degree of 
fucosylation can change throughout an APR event. In a study by Orczyk-
Pawilowicz et al., (2009), it was found that the degree of fucosylation was 
altered between the 2nd and 3rd trimesters of normal pregnancies. The plasma 
collected during the 2nd trimester lacked any fucose, however, a dramatic 
increase in the levels of fucose was seen within the plasma during the 3rd 
trimester, leading to the suggestion that this increase in fucose could be a 
regulatory step in the gestation period, and the potential use of AGP as a 
monitor for successful development.  It has been suggested by Gauldie et al., 
(1985) and Kushner and Mackiewicz (1987) that the qualitative patterns of 
APPs (of which AGP is included) is not influenced to a significant degree by the 
type of injury sustained; however, it is suggested by Goldberger et al., (1987) 
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and Kageyama et al., (1985) that there is a limited linear relationship between 
the severity of the injury suffered and the degree of plasma protein expression. 
 
1.2.3 Previous Studies of the Glycosylation Patterns of AGP in Disease 
 It has been seen in previous studies, that AGP glycosylation patterns can 
be altered by the APR when afflicted by disease. A study was carried out by 
Gallacher (2009) into the possible usage of AGP glycosylation patterns as a 
marker in early breast cancer. The research was a twofold analysis in which 
both the monosaccharide composition and oligosaccharide composition of AGP 
samples from patients with invasive cancer were compared to commercial AGP, 
age matched healthy AGP samples, benign samples, and non-invasive cancer 
samples. Results of the monosaccharide analysis showed that the invasive 
cancer samples possessed the highest concentration of fucose when compared 
to all other samples within the study. The hexosamine N-acetyl-galactosamine 
(GalNAc), a monosaccharide unit not found within the normal populations 
tested, was also found within the AGP collected from the invasive breast cancer 
group; showing that the APR can affect the types of monosaccharide units that 
can appear within AGP molecules. Within the oligosaccharide analysis portion 
of this study, there was an overall decrease in the complexity of the glycan 
chains with the increasing severity of the disease, i.e. more bi-antennary chains 
were seen within the invasive cancer sample group as opposed to more 
complex chains. As seen here, within breast cancer, there was an obvious 
difference between invasive cancer AGP samples when compared to “healthy” 
samples, and commercial AGP samples; thus, showing that AGP glycosylation 
patterns could be used as a potential biomarker in the detection of early stages 
of breast cancer. This study also showed a correlation between the levels of 
galactose, a main component of the branches of AGP, and the complexity (an 
increase in the number of peaks) of the branches. 
 Another study carried out by Anderson (2002) has shown the ability of 
AGP glycosylation patterns to be used to distinguish between different types of 
liver disease. Again the study used a twofold approach of analysis, by analysing 
the monosaccharides units and these molecules arrangements as 
oligosaccharide chains. The sample groups within this study were alcoholic liver 
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disease, hepatitis B, acute hepatitis C, chronic hepatitis C, cirrhosis, primary 
sclerosing cholangitis (PSC), and secondary biliary cirrhosis (SBC); these were 
then compared to “healthy AGP samples”. Within each sample group, an 
increase in the presence of fucose (hyperfucosylation) was found; with the 
hepatitis sample groups showing the highest levels of fucose within the study. 
The presence of N-acetyl-galactosamine (GalNAc) was also found within this 
sample group; GalNAc is not typically found within the monosaccharide 
composition of “healthy” AGP. The progression of hepatitis infections to 
cirrhosis would also show a decrease in the level of fucose as the hepatitis 
infection progresses. When analysing the oligosaccharide structure of the AGP 
within each of the sample groups, the study found that as each liver disease 
progressed in severity, the oligosaccharide make-up would increase in 
complexity, specifically showing an increase in the number of tri- and tetra-
antennary branches. Again, the most promising results were within the hepatitis 
sample groups, with acute hepatitis C samples showing an increased number of 
bi-antennary branches when compared to controls, before showing an increase 
in the number of tri- and tetra-antennary branches when then the infection 
shifted to chronic hepatitis C; with chronic hepatitis C infection showing an 
increased level of these branching types as well.  The glycosylation patterns of 
the AGP used within this study had shown to be able to successfully distinguish 
between different types of liver diseases, with the most success being found 
within the hepatitis sample groups and their progression to cirrhosis.  
 As seen in the above studies, the glycosylation patterns of AGP have 
shown the potential to be used as a biomarker for breast cancer and liver 
disease. It is this information that forms the basis for this study. Within this 
study, AGP glycosylation patterns shall be used to determine whether or not it is 
possible if a physical injury event can affect the AGP glycosylation pattern of 
AGP. The APR when brought on by physical injuries has shown to produce an 
increase in the serum concentration of AGP; however, could sports injuries 
produce an alteration in the glycosylation patterns of the AGP within the sample 
population of this project? Would there perhaps be individual glycosylation 
patterns seen between different sports injury types? By analysing the 
monosaccharide units and their arrangements within the AGP molecule as 
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glycan chains, by developing a “Glycosylation Fingerprint” as it were, this 
project hopes to answer these questions. 
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1.3 Mountain Biking 
1.3.1 Mountain Biking History 
Mountain Biking is a multi-disciplinary sport, of which consists of riding 
specially made mountain bikes over a selected distance or course. Mountain 
biking is split into different disciplines of which includes races and events 
recognised and officiated by the Union Cycliste Internationale (UCI); road 
cycling (road racing, and time trials in individual and team disciplines), track 
racing (containing three different disciplines, sprint events, endurance events 
and combined events), cyclocross, bicycle motocross (BMX) (involving 
supercross and freestyle events), and mountain biking, of which involves cross 
country (XC), cross country marathon, downhill (DH) and four cross (4X) 
events.  Each discipline has their own specific rules and competitions. For 
example, XC racing involves competitors racing each other over a 
predetermined track of varying heights and lengths en masse, while dirt jumping 
practitioners compete on a specially designed track where the focus of the 
competition is the satisfactory completion of airborne jumps. Competitors within 
any discipline must possess great strength, speed, endurance and skill when on 
their respective course. Most disciplines require the use of protective 
equipment, which includes at least helmet and gloves, but body armour and a 
full face helmet can be used to provide, and is recommended, for further 
protection (UCI Official Guidelines); some disciplines even require the rider to 
carry their own first aid kit (UCI Official Guidelines). XC is perhaps the “classic” 
form of mountain biking known the public. As previously mentioned, XC MTB 
involves the riders racing each other over a predetermined length of track 
(typically 3-6km in length following UCI Guidelines) with varying turns, climbs 
and descents. The first rider to cross the finish line is the winner of the event; 
the winner of the event scores 250 points, of which goes towards their collective 
score for the entire season. The winner of the world cup is the rider whom at the 
end of the season possesses the most points within their discipline. There is 
also a single world championship race held every season, the winner of which is 
crowned the world champion within their discipline. Both the world cup and 
world championship events are sanctioned by the UCI. As can be seen here, 
the sport of XC MTB possesses a focus on the endurance of the athlete to 
compete over the distances seen within a XC race, as opposed to the 
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showmanship skill needed by those competing within the dirt jumping circuit, or 
the speedy reaction times necessary for DH mountain biking. Those who want 
more difficulty than what XC MTB can provide can then move onto the sport of 
DH mountain biking should they wish. DH mountain biking will be the focus of 
this study, and will be covered next. 
 
1.3.2 Downhill Mountain Biking History 
The sport of DH mountain biking is a time based sport in which 
participants ride down outdoor trails and race tracks in the quickest time 
possible. Most courses tend to involve mountainous terrain (hence the name), 
of which the rider would have to navigate steep drops, large jumps and sharp 
turns from the starting post to the finish line. Often the rider would be travelling 
at increasing speed along the course which could result in serious injury should 
they fall. The governing body for professional DH mountain biking is the UCI 
based in Switzerland. Due to the inherent dangers involved within the sport, 
competitors are required to wear full face helmets to minimise the possibility of 
serious injury. Other protective equipment such as gloves, knee pads, body 
armour, are not required to be worn during world cup events, however, the use 
of such equipment is strongly recommended by the UCI. Local race rules are 
also in place with organisers enforcing stricter equipment checks-this situation 
of minimum protection levels is currently under review within the UCI. 
The sport of DH mountain biking was first developed as a sport in the 
late 1970’s in the U.S.A., steadily growing in popularity on each side of the 
Atlantic, until it first became a recognised championship sport in 1990 in the UCI 
Mountain Biking Championships held in Colorado; the World Cup Series has 
taken place annually since 1993. Seven world cup races take place between 
the months of March and September every year on UCI approved world 
championship courses. Qualified riders take part within these races, gaining 
points based on their time based performance within these races; i.e. the rider 
who places first in a world cup race will gain 250 points which will go towards 
their score within the overall world cup standings. The winner of the world cup is 
the rider, who at the end of the seven event races has the most points in the 
world cup standings. In addition to the world cup, there is also the world 
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championship race every year as well. This is one race of which the competitor 
who possesses the fastest completed run once all competitors have raced will 
be crowned the DH MTB world champion.  
However, DH mountain biking is not only a sport for professionals; there 
are many outdoor parks of which possess trails and race tracks for amateurs 
looking to sharpen their skills or even just for fun. Typically these trails are 
graded based on the perceived difficulty of the course; Glentress  Forest 
Mountain Biking Trails (located in the Scottish borders) possesses four trail 
difficulties, green (easy, 3.5-4.5km in length, typical completion time of 0.5-1 
hour), blue (moderate, 16km, 2-4 hours), red (difficult, 18km, 1.5-3 hours) and 
black (severe, 29km, 3-5hours); information taken from 7stanes Glentress and 
Innerleithen webpage. It is also possible for riders to partake on free style 
routes where they can freely ride the terrain rather than staying on a particular 
trail. There is also a freeride park within Glentress of which possesses a series 
of jumps, table-tops and assorted obstacles of which allow the rider to perform 
tricks on their bike as they see fit. The nature of these obstacles can result in 
injury should a rider fall off of them.  Again, it is recommended by the Forestry 
Commission that each rider wear an appropriate cycle helmet and gloves, in 
addition to any other protective clothing they may wish to wear in order to 
minimise injury. It has been seen that by wearing a helmet, a rider can reduce 
the risk of head injury by 85% and brain injury by 88% (Schwellnus and 
Derman, 2005). 
As previously mentioned, the sport of DH mountain biking was chosen 
within this project due to the inherent challenges of the sport to even the most 
seasoned rider. The nature of the sport, the ever increasing speed while riding 
downhill, the drops, the jumps and sharp turns can lead to serious injuries as a 
result of a momentary lapse in concentration while riding or executing a jump. 
The natural terrain of the trail may not afford the rider a soft landing on impact, 
and not all riders wear all the safety equipment available to them; injuries can 
happen to any rider while they’re riding the trail.  
A study carried out into recreational mountain biking injuries by Aitken et 
al., (2011), using mountain bikers from Glentress Mountain Biking Trails and 
five local medical facilities in the surrounding area during a 12 month period of 
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study. During the period of study, 130,900 cyclists visited the park, and of these 
cyclists, 202 were treated at one of the five local medical facilities for an injury, 
resulting in 1.54 injuries per 1000 cyclists. Of these cyclists, 88% (178) of the 
injured cyclists were male, while 12% (24) were female. The greater 
participation of the sport by the male gender can also be seen within the 
members of the National Off-Road Bicycle Association (NORBA), with 87% of 
its members being male (USA Cycling, 2011). 16% of the injured cyclists 
required hospital admission. Of the 202 cyclists treated at the local medical 
facilities, 182 individuals were available for a further interview. Within the group 
of 182 injured individuals, 289 injuries were suffered, which resulted in 1.6 
injuries per biker. Injury types were classified as wounding (affecting 63% of 
cyclists), soft tissue injury (37% of cyclists), fracture (37% of cyclists), head 
injury (13%) and dislocation (8%).  Within Glentress, 45% of the injuries studied 
were suffered on the freeride trail, while 30% of injuries were suffered on the 
red route, 11% were suffered on the blue route and the black route 
respectively, while 1% of injuries were suffered on the green route, thus, 
showing that injuries can happen on any trail difficulty. 
A review into mountain biking injuries by Krosnich et al., (1996) found 
that for every 100 hours of mountain biking, 4.34 riders will be injured as a 
result of DH mountain biking, higher than the study carried out by Aitken et al., 
(2011), and higher when compared to 0.37 riders who partake in XC mountain 
biking. Additionally, another 1996 study by Krosnich et al., found that the most 
common injury to riders when falling off of their bikes was that of abrasions; 
what is also interesting to note is that during this multi-disciplinary study, 81.4% 
of injuries that occurred within the scope of the study happened during DH 
mountain biking. A further study by Chow and Krosnich (2002) supports these 
findings, they found that 70.5% of injuries present within the study were minor 
injuries and involved the extremities as opposed to the head and the abdominal 
cavity, while the incidences of concussions were found to be not uncommon 
either, with several studies reporting the injury incidence to be from 3-13% of 
injuries studied (Krosnich et al., 1996, Krosnich et al., 2002). 
It is also worth noting that while the majority of injuries that happen to 
riders may be minor, this is typical when the rider is falling off of their bike to the 
side, rather than heading over the handlebars. Krosnich and Chow (2002) found 
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that riders who fell over their handlebars would be more likely to result in head 
and neck injuries (Apsingi et al., 2006), while falling off to the side of the bike 
would result in the abrasions to the legs seen above. One study of trauma 
registries by Kim et al., (2006) showed that orthopaedic injuries were the most 
common trauma admission as a result of mountain biking crashes, with 46.5%. 
Of these admissions, 66% of patients required surgery, with one patient even 
dying from his injuries. Fatalities occurring during riding are rare, in a study by 
Rivara et al., 1997 a cyclist died after crashing without wearing a helmet, while 
another cyclist died after suffering from a ruptured diaphragm (Alvarez-Segui et 
al., 2001). Interestingly, however, a study by Gaulrapp et al., (2001), found that 
the most common site for injury was that of the leg, specifically, the calf and 
knee; Gaulrapp et al., then go on to state that the most common fracture within 
their study was that of the shoulder, as opposed to the most common site of 
injury. A study by Jeys et al., (1999) further supports this result.  
However, it has also been reported that some cyclists have suffered from 
overuse injuries throughout the course of their riding. Overuse injuries are 
defined as injuries having been caused by repetitive actions leading to muscle, 
tendon and soft tissue damage. It was found in a 1998 study by Dingerkus et 
al., that 45% of the 208 mountain bikers interviewed during their study were 
suffering from an overuse injury. The most common overuse injury areas within 
the body are saddle area, neck, hands, lower back, knee joints, and wrists 
(Froböse et al., 2001). 
Perhaps, what is most interesting of all to note, is that it is possible that 
riders who are competing within a DH mountain biking race, are four times more 
likely to become injured than those who are riding a trail for fun (Krosnich and 
Rubin, 1994); with the main contributing factors for injury found to be loss of 
control, the high speed descents present within a trail and the competitive 
atmosphere itself. This is understandable as every racer wants to win the race 
they are taking part in; it is interesting to note that within Britain’s only UCI 
World Cup approved course (Fort William), that speeds of 60+km/h are possible 
on the course (reference data from our own lab). Should a rider fall while 
travelling at these speeds down the descending course, it is fully possible that 
an injury could be very severe. As it can be seen here, a great deal of 
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experience and skill is necessary to not only navigate the trail, but to do so in as 
fast a time as possible and in the safest way possible.  
In summary, it is seen that while those with experience may not become 
injured very often, it is fully possible for the most seasoned rider to injure 
themselves while riding downhill. The potential for injuries due to the terrain of 
the trails and the speeds at which the riders can reach and Edinburgh Napier 
University’s own strong links with DH mountain biking riders make DH mountain 
biking an ideal choice within this project into looking at the glycosylation 
patterns of physical injuries. The awareness that Edinburgh Napier University 
possesses within the mountain biking community and the steps taken within the 
recruitment of this project means that time between injury occurrence and 
venepuncture will be as short as possible as is convenient for the injured 
volunteer; which in turn, will provide a more accurate picture of the glycosylation 
patterns of the AGP within the injured volunteer in the time since their accident. 
Full ethical approval for this project was granted by the Edinburgh Napier 
University Faculty of Health, Life and Social Sciences Research Ethics and 
Governance Committee.  
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1.4 Project Aims 
 The main aim of the project  was to determine whether or not the acute 
phase response altered the glycosylation patterns of the AGP of injured 
mountain bikers who have suffered a physical injury as a result of DH mountain 
biking. Furthermore, the project sought to determine whether or not different 
injury types resulted in the development of different glycoforms of AGP; i.e. will 
a shoulder injury produce different types of altered AGP as opposed to a leg 
injury. The final aim of this project was to determine whether or not the altered 
glycoforms of AGP could be used to diagnose a potential physical injury. The 
information gathered within this project would then be used as the basis for 
further study within this area. Figure 3, below, shows the plan of action for this 
project. 
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Figure 3. Project Action Plan  
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2.1 Materials 
2.1.1 Volunteer Samples 
The Edinburgh Napier University Ethics Committee approved the 
acquisition of ~5ml blood samples from volunteers who have been injured while 
taking part in DH mountain biking. In this preliminary study, any injury which 
occurred while taking part in DH mountain biking was eligible for use within this 
study. Volunteers were recruited via word of mouth, email, and the distribution 
of project descriptive leaflets to mountain biking centres and trails. An initial 
~5ml blood sample was taken from project volunteers and placed into EDTA, 
anti-coagulant lined tubes, and the volunteer filled in an Napier University 
ethically approved questionnaire to categorise the injury they experienced. 
Should the volunteer wish, they were invited to provide a second ~5ml blood 
sample after their injury had healed to provide a “healthy control” to act as a 
comparison of healthy AGP to injury AGP. One sample remained as an 
“unknown” throughout the study, to determine the possibility of AGP being used 
as a diagnostic marker for sports injury. This sample, XX001 ?/?, was purified, 
its glycosylation pattern analysed and compared to the known injury AGP 
samples to determine if there are any similarities or differences between the 
unknown sample and the known injury samples.  
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Sample Number Injury Area (Type) M/F Age 
SH001 18/3 Shoulder(Bruising 
and Cuts) 
M 22 
GI001 7/6/10 General 
Injuries(Bruising 
and Cuts) 
M 41 
EW001 20/3 Elbow(Abrasions) M 34 
LG001 12/9 Leg(Abrasions) F 30 
SH002 7/6/10 Shoulder(Break) M 42 
WR001 11/16 Wrist(Fracture) M 21 
XX001 ?/? Unknown F  
GI001 7/6/10 Healed M 42 
EW001 20/3 Healed M 34 
LG001 12/9 Healed F 30 
WR001 11/16 Healed M 21 
Table 1. Patient Demographics 
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2.1.2 AGP Purification 
 HPLC grade water was purchased from Rathburn Chemicals Ltd 
(Walkerburn, UK). 10ml Bio-rad columns were purchased from Bio-rad (Hemel 
Hempstead, UK). Glacial acetic acid, Polyethylene glycol (PEG) 3350, 
Potassium chloride, Potassium thiocynate, Reactive blue 2 sepharose 
(Cibacron blue 3GA), Red sepharose CL-6B, Sodium acetate, Sodium azide, 
Sodium chloride, and Trizima were purchased from Sigma-Aldrich (Poole, UK). 
Blood samples were PEG separated through the use of an eppendorf centrifuge 
5415C, and samples were concentrated using a Christ RVC 2-18 concentrator 
purchased from SciQuip Ltd, Shrewsbury, UK. Ethanol was purchased from 
Bamford Laboratories Ltd, before being diluted to 10% (v/v). A Pharmacia LKB 
Pump P-1 was used to load buffers and samples to the columns, a single path 
optical UV-1 monitor and control unit was used to measure the absorbance of 
the running samples at 280nm before recording the samples absorbance using 
a Servogor 120 chart recorder; all of which were purchased from Pharmacia, 
UK.    
 
2.1.3 De-salting of Injury AGP Samples 
 HPLC grade water was purchased from Rathburn Chemicals Ltd 
(Walkerburn, UK) and Amicon centrifugal filter tubes with a MW cut off of 
10,000 were used and purchased from Millipore Ltd (Hertfordshire, UK). A 
Universal 320 (large scale) centrifuge (Sartorius, UK) was used to spin the NaCl 
out of the injury AGP samples. A Christ RVC 2-18 concentrator (from SciQuip 
Ltd, Shrewsbury, UK) was used to concentrate samples down. 
 
2.1.4 Determination of level of AGP in samples 
 Calibration curves for reference were produced through the use of 
commercial AGP purchased from Sigma-Aldrich; and HPLC grade water was 
used (Rathburn Chemicals Ltd, Walkerburn, UK). The absorbance of 
commercial and injury AGP samples were read using a BioMate 3 
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spectrophotometer purchased from Thermo Fischer Scientific (Loughborough, 
UK). 
 
2.1.5 High pH Anion Exchange Chromatography 
2.1.5.1 Monosaccharide Analysis 
 The necessary monosaccharide units for the monomix standards, 2-
deoxy-D-galactose, fucose, galactose, glucosamine, mannose; in addition to the 
commercial AGP, 2ml hydrolysis reaction aluminium lined vials, Dowex -
50WX8-100 cation exchange resin (hydrogen form, 8% carbon loading, dry 
mesh 50-100) (which replaced the now out of stock Dowex- 50X12-100 cation 
resin) and 4M hydrochloric acid was purchased from Sigma-Aldrich (Poole, UK). 
HPLC grade 2M trifluorouacetic acetic acid (TFA) was purchased from Thermo-
Fischer Scientific (Loughborough, UK). HPLC grade water was purchased from 
Rathburn Chemicals Ltd, Walkerburn, UK. 50% w/v sodium hydroxide was 
purchased from VWR International Ltd (Lutterworth, UK). Solutions were 
degassed through the use of a helium cylinder and a Dionex degas module, to 
perform chromatography, a CarboPac PA-100 analytical (4x250mm) column 
and a (4x50mm) guard column were used on a Dionex 600 system with pulsed 
electrochemical detection (PED) and Chromeleon 6 software to record 
analytical results, all purchased from Dionex, Camberley, UK (now owned by 
Thermo-Fischer Scientific, Loughborough, UK). 
 
2.1.5.2 Oligosaccharide Analysis 
 The necessary peptide-N-glycosidase F (PNGase F) (purified from 
Flavobacterium meningosepticum), 10% NP-40 buffer and NE G7 buffer were 
purchased from New England Biolabs Inc. (Hertfordshire, UK). HPLC grade 
water was purchased from Rathburn Chemicals Ltd, Walkerburn, UK. Ethanol 
was purchased from Bamford Laboratories Ltd (Rochdale, UK), the AGP N-
linked glycan library was purchased from Prozyme (Europa Bioproducts Ltd, 
Cambridgeshire, UK). The 50% w/v sodium hydroxide was purchased from 
VWR International Ltd (Lutterworth, UK). sodium acetate, a CarboPac PA-100 
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analytical (4x250mm) column and a (4x50mm) guard column were used on a 
Dionex 600 system with a GP50 gradient pump, ED40 electrochemical and 
pulsed electrochemical detection to carry out analytical analysis of samples 
using Chromeleon 6 software to record analytical results, all purchased from 
Dionex, Camberley, UK (now owned by Thermo-Fischer Scientific, 
Loughborough, UK). 
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2.2 Methods 
2.2.1 Sample Acquisition  
As this is a preliminary project, there was no bias shown towards 
favouring a certain type of injury within the volunteer selection process. The 
procurement of samples was solely dependant on the willingness of volunteers 
to take part. Volunteers were recruited for this project through word of mouth, 
email correspondence between project organisers and cycling clubs, and 
through the use of project descriptive leaflets being handed out at Mountain 
Biking events and displays. Each project volunteer must have been injured 
while riding a Mountain Bike, and must have been injured at the time the 
venepuncture was carried out by the qualified phlebotomist. Volunteers were 
asked to sign a consent form to take part within the project (or have their 
parent’s written consent if they were under 18) before the venepuncture could 
take place where they would then provide a 5ml blood sample, and afterwards, 
they were then asked to fill out a short questionnaire with which categorisation 
of their injury could then take place for project records. Should the volunteer 
then wish, once they had healed from their injury they could then come back to 
the University at a later date to provide a second 5ml blood sample to provide a 
reference comparison of their own healthy AGP of which could then be 
compared to their own injured AGP glycosylation patterns.  At this time of 
writing (May, 2012), seven volunteers have provided a blood sample, with which 
further analysis has then progressed, while four of those volunteers have also 
provided a second blood sample for further healthy comparisons.  
Within these samples, one sample has purposely remained as an “unknown”; 
this sample was classified as XX001 ?/? to prevent the identification of the 
sample and the injury the rider suffered while riding downhill. This sample was 
then purified normally according to protocols, and the AGP within the sample 
was analysed by HPAEC as normal along with all of the known samples. The 
aim of this experiment was to determine whether or not there would be any 
diagnostic capabilities within the glycosylation patterns of the AGP. The 
resultant chromatographs of the analysis will be compared to the other known 
samples to determine if there are any similarities or differences between the 
unknown sample and the known injury samples. 
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2.2.2 Removal of Red Blood Cells from Samples 
 Once the samples were taken from the project volunteer, they were 
prepared before use within the HPAEC. To begin, samples were removed from 
the venepuncture collection tubes, and transferred into clean eppendorf tubes. 
Polyethylene glycol (PEG) 3350 was added to the blood samples (40% w/v), 
0.4g of PEG was added to each 1ml sample. The contents of the eppendorf 
were lightly vortexed and then placed in a fridge at 4oC over night. The sample 
eppendorf was then placed in an eppendorf centrifuge at 14,000rpm for 30 
minutes. The clear supernatant of the sample was then transferred into another 
fresh eppendorf, the pellets were then discarded; samples would be spun again 
at 14,000rpm for 30 minutes should they require. Samples were then placed 
within the freezer at -20oC until use within the project. 
 
2.2.3 Low Pressure Chromatography- Blue Column 
 Three proteins were left within the sample once they have been through 
the PEG 3350 preparation; these proteins are albumin, α-anti-trypsin(AAT), and 
the desired alpha-1-acid glycoprotein (AGP). In order to procure pure AGP, the 
albumin and AAT had to be removed from each sample. Firstly, albumin was 
removed from the sample, which was achieved by using a low pressure 
chromatography column filled with reactive blue sepharose beads. When a 
sample was run through the column, albumin would bind to the sepharose 
within the column, allowing AAT and AGP to pass through the column and the 
detector. 
 The necessary buffers needed for this stage were prepared first. Elution 
buffer (Blue) was prepared by dissolving 7.45g of potassium chloride, 6.05g of 
Trizima, and 0.2g of sodium azide in distilled water using a magnetic stirrer, 
before being made up to one litre using more distilled water. The pH of the 
solution should be that of pH7; if not, 2M HCl should be added to the buffer until 
it reads pH7. Elution buffer (Blue) is necessary to move the samples through 
the column and the detector.  
 As albumin was bound to the sepharose following the passage of AAT 
and AGP through the column, albumin was removed from the column by the 
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addition of a description buffer to the column before another sample could be 
loaded. Description buffer was made by dissolving 12.15g of potassium 
thiocynate in some elution buffer (Blue) using a magnetic stirrer, and making the 
solution up to 250mls by the addition of more elution buffer (Blue). The 
description buffer would remove the bound albumin from the sepharose within 
the column, to prevent clogging of the column with albumin and sample 
contamination between samples. 
 The column was then made up by adding 5mls of reactive blue 
sepharose beads to a bio-rad column, allowing the beads to settle and allowing 
the ethanol to elute out into a waste jar. More sepharose can be added to the 
column until it reads 5mls of sepharose beads. The column can then be stored 
in elution buffer (Blue) until use. 
 The necessary equipment should then be set up in the following 
orientation: 
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Figure 4. Equipment Orientation for Low Pressure Chromatography 
  
 
 
 
 
 
 
 
 
 
 
 
32 
 
 Elution buffer (Blue) was then run through the column and the detector to 
equilibrate the column; the buffer was allowed to pass into the waste jar. Once a 
“flat base line” was achieved on the detector, the column was equilibrated and a 
sample was then added to the column. The sample was added into the column 
by removing the pump tubing from the elution buffer (Blue) bottle and placing 
the tubing into the eppendorf. Once the eppendorf was empty, the pump tubing 
could then be placed back into the elution buffer (Blue) bottle. 
 Once the chart recorder showed a line appearing above the baseline, the 
sample was collected by removing the waste jar tubing from the waste jar and 
placing it into a centrifuge tube. A single peak was being detected at 280nm, of 
which would contain AGP and AAT, with albumin being bound to the column. 
Once the peak had returned to baseline, all the AGP/AAT had passed through 
the column and the detector, thus, the waste tubing was placed back into the 
waste jar.  
 Description buffer was then passed through the column to remove 
albumin from the sepharose beads into the waste jar. A small peak appeared on 
the chart recorder, this is the albumin passing through the chart recorder. Again, 
once the chart recorder was back at baseline, all albumin had been removed 
from the column. Should another sample have been applied to the column, the 
column was re-equilibrated by addition of more elution buffer (Blue), to remove 
all traces of description buffer from the column. Once a “flat base line” had been 
achieved again, another sample could then be added to the column. Should the 
column have been needed again at a later date, then addition of 10% ethanol to 
the column and storage in the fridge at 4oC until next use was necessary. 
 
2.2.4 Drying Down AAT/AGP Mixture-Interim Step Between Blue and Red 
Columns 
 The gyrovap was turned on and given time to come down to the 
necessary temperature of -60oC; typically around 20 minutes. Once ready, the 
centrifuge tubes containing the AAT/AGP mixtures were placed within the 
appropriately sized rotor, care being taken to make sure the samples were 
balanced within the gyrovap. The centrifuge was then set to spin for two hours; 
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in terms of regular practice, samples tend to evaporate roughly around 1ml per 
hour within the centrifuge tubes, samples within smaller vessels such as 
eppendorf tubes could take longer. Samples continued to be spun until each 
sample reached 2ml of solution. Samples could then be stored in the freezer at 
-20oC until next use. 
 
2.2.5 Low Pressure Chromatography- Red Column 
 There was a further need to remove AAT from the AAT/AGP mixture 
within each sample. This was achieved by passing each sample through a 
column filled with reactive red 120-agarose type 3000 Cl beads. The red 
agarose beads bound AAT to the column, allowing the desired AGP to pass 
through the column. The buffers needed for this step of AGP purification were 
prepared before low pressure chromatography could begin. 
 Elution buffer (Red), the mobile phase for this step of AGP purification, 
was prepared by dissolving 4.102g of sodium acetate in 50ml of distilled water, 
before being made up to 250ml using more distilled water. 1.15ml of glacial 
acetic acid was then added to a 100ml volumetric flask, which was then filled to 
100ml using distilled water. Elution buffer (Red) was then made up by adding 
136ml of sodium acetate solution and 13.5ml of glacial acetic acid solution to a 
1l volumetric flask, which was further made up to 1l using distilled water. 
 The cleaning buffer needed for this purification stage was prepared by 
dissolving 5.84g of NaCl in 25ml of elution buffer (Red), before making the 
solution up to 100ml using more elution buffer (Red).  This buffer would remove 
the bound AAT from the column, allowing it to pass into the waste jar, 
preventing build up of AAT within the agarose beads within the column, and any 
possible contamination of further samples with leftover trace material from 
previous samples. 
 As before, a bio-rad column was filled up to 5ml with the reactive red 
120-agarose type 3000 Cl beads, allowing the 0.5M NaCl elute to run out into 
the waste jar, and compacting the red agarose beads within the column, topping 
up the column further to read 5ml when filled with red agarose beads.  
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 Furthermore, the necessary equipment was set up in the same 
orientation as seen in figure 4. Elution buffer (Red) was run through the column 
to achieve equilibration, with equilibration being shown with a “flat base line” on 
the chart recorder. Once equilibration was achieved, the sample was added to 
the column by taking the buffer tube out of the buffer bottle and placed into the 
centrifuge tube containing the AAT/AGP mixture. Once the entire sample was 
pumped into the column, the pump tubing was then placed back into the elution 
buffer (Red) bottle. Again, when a peak appeared above the baseline, the waste 
jar tubing was taken out of the waste jar and placed into a fresh centrifuge tube 
for collection of isolated AGP. 
 When the peak fell below baseline, collection was stopped and the waste 
tubing placed back into the waste jar. The column was then cleaned using 
cleaning buffer, this removed the bound AAT from the column while the elute 
was allowed to run into the waste jar; a small peak showing on the chart 
recorder, this was the AAT removed from the column. Once this peak 
decreased below baseline, cleaning had completed and should another sample 
have been needed to run through the column, then the column was further re-
equilibrated before the addition of another sample. The column could then be 
stored in 10% Ethanol at 4oC should no further samples be run through the 
column. Again, samples were then dried down to 2ml each within the gyrovap 
before further use in the project.   
 
2.2.6 De-salting Centrifugation 
 Before the mass of AGP within each injury sample could be determined 
using the spectrophotometer, it was necessary to remove the NaCl molecules 
introduced into the AGP sample during the red agarose AAT removal, this NaCl 
can interfere in the reading of the mass of AGP within the spectrophotometer. 
This was achieved by placing each 2ml sample within a clean centricon filtered 
centrifuge tube (each possessing an MW of 10,000), placing each sample within 
the top compartment of the centrifuge tube. Each sample was then topped up 
with a little HPLC grade water until the solution reached the rim of the top of the 
tube. Each centrifuge tube was then placed within a centrifuge, making sure to 
balance the centrifuge before spinning the samples at 4000rpm for 30 minutes 
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at 23oC. Removal of the NaCl molecules was achieved by using centrifugal 
force as the centrifuge forced all the smaller NaCl and water molecules out of 
the top layer through the 10,000 MW filter out to the bottom layer of the tube; 
allowing the larger AGP molecules to stay in the top layer of the centrifuge tube. 
 After 30 minutes had passed, each sample was taken and the bottom 
layer of elute (this is NaCl water) was emptied into a sink. Furthermore, the top 
layer of elute was then topped up with more HPLC water, and placed back 
within the centrifuge for another cycle of 30 minutes. This process was 
repeated, until the top layer of elute passed near completely through the filter 
when topped up with HPLC water; this indicated that the sample was then pure 
AGP without the NaCl molecules within; this process would roughly take around 
6 cycles. Each AGP sample was then be topped up with 1ml of HPLC water and 
lightly shaken to encourage re-suspension before being transferred into fresh 
eppendorf tubes and dried down to completion (removal of all liquid) within the 
gyrovap. Once completely dried down, each sample was re-suspended in 1ml 
of HPLC water and lightly vortexed to encourage re-suspension. Each sample 
could then be placed within the spectrophotometer to determine the mass of 
AGP within each sample.  
 
2.2.7 Determination of Mass of AGP within Injury Samples using 
Absorbance at 280nm 
 The mass of AGP within the injury samples was too small to measure 
accurately with scales, this was achieved by measuring the absorbance of the 
samples at 280nm within the spectrophotometer before comparing this to a 
standard curve of AGP absorbance which was constructed using a commercial 
AGP standard through the use of the Beer Lambert Law. The Beer Lambert 
Law states that there is a linear relationship between absorbance and the 
concentration of an absorber of electromagnetic radiation. Firstly, a stock 
solution of AGP was made up by dissolving 6mg of commercial AGP within 2ml 
of HPLC water. Once the absorbance of this sample had been determined, then 
another standard 0.5mg/ml less in quantity was made up from the preceding 
sample using the formula C1V1=C2V2. For example, the standards within this 
study were calculated using the following; in all calculations, V1 is the value to 
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be determined, while all standards were to be made up to 1ml (V2) using HPLC 
water: 
 3mg/ml standard= 6mg of commercial AGP in 2ml of HPLC water. 
 2.5mg/ml standard, C1= 3mg/ml, C2= 2.5mg/ml 
V1= (C2V2)/C1= (2.5x1)/3= 0.833ml of 3mg/ml  
V2= 1ml= 1-0.833ml= 0.167ml of HPLC water. 
 2.0mg/ml standard, C1= 2.5mg/ml, C2=2mg/ml 
V1= (2x1)/2.5= 0.8ml of 2.5mg/ml standard 
V2= 1-0.8= 0.2ml of HPLC water. 
 1.5mg/ml standard, C1= 2.0mg/ml, C2=1.5mg/ml 
V1= (1.5x1)/2= 0.75ml of 2.0mg/ml standard 
V2= 1-0.75= 0.25ml of HPLC water. 
 1mg/ml standard, C1=1.5mg/ml, C2= 1mg/ml 
V1= (1x1)/1.5= 0.667ml of 1.5mg/ml standard 
V2= 1-0.667= 0.33ml of HPLC water. 
 0.5mg/ml standard, C1=1mg/ml, C2=0.5mg/ml 
V1= (0.5x1)/1= 0.5ml of 1mg/ml standard 
V2= 1-0.5= 0.5ml of HPLC water. 
 0mg/ml standard= 0mg of AGP, 1ml of HPLC water.  
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Quantity (mg) AGP Vol. (ml) HPLC Water Vol. 
(ml) 
Standard Total 
Volume (ml) 
3.0 1.00 0.00 1.0 
2.5 0.83 from 3mg/ml 
std 
0.17 1.0 
2.0 0.80 from 2.5mg/ml 
std 
0.20 1.0 
1.5 0.75 from 2mg/ml 
std 
0.25 1.0 
1.0 0.67 from 1.5mg/ml 
std 
0.33 1.0 
0.5 0.50 from 1mg/ml 
std 
0.50 1.0 
0.0 0.00 1.00 1.0 
Table 2. AGP Dilution Chart 
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 Once these solutions had been made up within fresh eppendorf tubes, 
each sample was then placed within a quartz cuvette and placed within the 
spectrophotometer at 280nm, making sure to clean the quartz cuvette between 
samples; results were recorded for each of the commercial AGP samples, 
before placing the injury samples within the spectrophotometer and reading 
those results. 
 The results (minus the injury samples) were placed within an excel table, 
creating a scatter graph with AGP mass on the X-Axis and Absorbance on the 
Y-Axis, adding a trendline to the graph and displaying the equation on the 
graph; a gradient was then gained as “y=..........X”. In practice this was shown 
as y=0.8671X, which was then rearranged to X=y/0.8671, where X is the mass 
of AGP to be determined, while y is the samples absorbance, this information is 
found within the graph below. 
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Graph 1. Calibration Curve of AGP Concentration (mg/ml) Against 
Absorbance at 280nm 
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 Once the mass of AGP within the samples had been determined, it was 
then necessary to determine how much AGP was needed for the next stages of 
the project. This was determined using C1V1=C2V2, where the concentration of 
the AGP within the purified sample was multiplied by its volume, which was 
equal to the concentration of the AGP within a second sample when multiplied 
by its volume. In this case the equation was rearranged to determine the 
volume needed for the next steps of preparation (V2), which required specific 
amounts of AGP to complete. The rearranged equation was V2= (C2/C1) x V1; 
using LG001 12/9 (which was determined to possess an AGP concentration of 
1.727mg/ml) as an example: 
V2= (50µg/1727µg) x 1000µl= 29µl of LG001 12/9 was needed for acid 
hydrolysis breakdown (monosaccharide preparation). 
V2= (100µg/1727µg) x 1000µl= 58µl of LG001 12/9 was needed for enzyme 
digestion breakdown (oligosaccharide preparation). 
Using this information, it was then possible to move on with further preparation 
for testing within this project. 
2.2.8 Further Preparation for Monosaccharide Analysis 
2.2.8.1 Acid Hydrolysis of Injury AGP samples (Monosaccharide Analysis 
Preparation) 
 In order to determine the glycosylation pattern for each injury sample, it 
was necessary to determine the specific monosaccharide units that make up 
the carbohydrate portion of the AGP molecule, before analyzing the 
arrangement of each of these monosaccharide units as glycan 
(oligosaccharide) branches. To analyze the monosaccharide units within the 
HPAEC, it was necessary to first break the glycosidic bonds within the AGP 
molecule that bond every monosaccharide unit to each other and to the AGP 
protein backbone. This was accomplished by acid hydrolysis, which breaks 
down the bonds between monosaccharides through a combination of acidic 
application and heat. 
 Firstly, a heat block was set up and time was given to allow it to reach 
the necessary temperature of 100oC for acid hydrolysis. From here, the 
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calculated volumes of injury sample AGP were transferred into fresh aluminium 
lined glass vials; the aluminium lining would prevent any escaping evaporate. 
Should the calculated volumes of AGP have equated to more than 100µl, then 
these volumes were dried down to completion and then reconstituted in 100µl of 
HPLC water. Once the samples were in the aluminium vials, then 100µl of 2M 
trifluorouacetic acetic acid and 50µl of 4M hydrochloric acid were added to each 
sample before screwing the black lid on each sample tightly and before placing 
them into the heat block for 4 hours. Note that the lids must be checked after 2 
hours as they can become loose due to the expanding glass and plastic of the 
lids, if they are loose, then they must be tightened. Once the allotted time had 
passed, samples were taken off of the heat block and placed onto the bench to 
cool to a safe temperature before being handled within the next stage of the 
project. 
2.2.8.2 Dowex Separation of Injury AGP samples (Monosaccharide 
Analysis Preparation) 
 Now that the monosaccharides were now free within the glass vials, it 
was then necessary to separate the free monosaccharides from the leftovers of 
the protein backbone within the sample. This was accomplished by passing the 
hydrolysed AGP sample through a column filled with Dowex resin. A Dowex 
column is simply a pasteur pipette plugged with half a centimetre of glass wool, 
before placing the pipette into a retention stand above a waste beaker, then 
filled with a centimetre of Dowex resin and allowing the elute to run out into the 
waste beaker. The Dowex resin should be pH4 before being used in this 
procedure; if not, then the beads should be washed with HPLC water until the 
required pH is reached. 
 Once the Dowex resin had been added to the column, then six 1ml 
fractions of HPLC water were ran through the column, one at a time, to achieve 
column equilibration. Then an AGP injury sample was run through the column, 
collecting the elute in a fresh eppendorf. A further two 1ml fractions of HPLC 
water were added to the column, again collecting the elute in an eppendorf 
tube; resulting in two eppendorf tubes filled with 1ml of a mixture of free 
monosaccharides suspended within HPLC water. Should anymore samples had 
required processing through a Dowex column, then a new column was made 
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and equilibrated for every sample. Each sample’s two eppendorf tubes were 
then dried down to 0.5ml before being added together to make one 1ml 
eppendorf tube for each sample, which was then further dried down to 
completion and reconstituted in 195µl of HPLC water and 5µl of internal 
standard (2-deoxy-D-galactose); these reconstituted samples were then be 
transferred into fresh 1.5ml Dionex vials for analysis within the HPAEC. 
 
2.2.8.3 Preparation of Monosaccharide Control (Monomix) for use in the 
HPAEC 
 The monomix was this project’s control solution for monosaccharide 
analysis; it is a five sugar unit solution that was ran through the HPAEC prior to 
an analytical run to show that the HPAEC was working as expected, and allow 
the appropriate comparison and quantification of any monosaccharide sugars 
detected within the injury samples tested to take place. The monomix contained 
the four sugars that are typically found to make up AGP; these are fucose, 
glucosamine, galactose and mannose. Also present within the solution was an 
internal standard (2-deoxy-D-galactose) which allowed quantification of the 
other carbohydrates in the monomix. 
 Firstly, a stock of each carbohydrate was made up by dissolving 10mg of 
each of the sugars in 10ml of HPLC grade water, creating a carbohydrate 
concentration of 1mg/ml. From this, 200µl of each sugar was transferred into a 
fresh eppendorf tube, creating a 1ml solution containing equal amounts of each 
of the sugars. Once the 1ml monomix was complete, 20µl of the monomix 
solution was transferred into a fresh 1.5ml Dionex vial; then 180µl of HPLC 
grade water was added to the solution bringing the total volume within the vial 
to 200µl, creating a 1 in 10 dilution of the original monomix. This dilution was a 
necessary step as the sugars, undiluted, could clog the column over time; it also 
allows a clearer separation of the five peaks that the five carbohydrates are 
expected to produce in a working analysis. 
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2.2.8.4. Monosaccharide Analysis by HPAEC 
High pH Anion Exchange Chromatography (HPAEC) separates a 
substance out via the degree of negative charge produced by substances basic 
components. In this instance, HPAEC was used to separate out a sample of 
AGP based on the degree of negative charge produced by the 
monosaccharides found within the tested samples. Within chromatography, a 
solid phase and a mobile phase are needed; a Carbo-Pac 100 column was the 
solid phase and a solution of 3%/97% sodium hydroxide(NaOH)/HPLC grade 
water was used as the mobile phase to move the samples through the column 
at a rate of 0.5ml a minute on an isocratic gradient. The samples’ base sugar 
components were then detected using a PED electrochemical detection system, 
which would highlight the negative charges within each of the sugar 
components, resulting in a chromatograph which would show the user which 
sugar has come off the column at a precise time and order.  
In this case, the prepared injury AGP samples were placed within the 
HPAEC, alongside a monomix control; care being taken to place the monomix 
first, as this would show the HPAEC was working properly, and, therefore, could 
prevent sample wastage should a problem arise within the HPAEC. Once the all 
the samples were ready, the analytical run could begin, starting off with the 
monomix before automatically proceeding onto each sample. A typical running 
time for one sample’s separation run was 30 minutes (45 minutes when 
including a regeneration run to clean the column), thus, if a lot of samples 
needed processed, appropriate time management measures were taken. Once 
finished, samples were kept within the freezer for reference, and the injury AGP 
sample chromatographs were printed off and used for future analysis. 
                     
2.2.9 Further Preparation for Oligosaccharide/Glycan Branching Analysis 
2.2.9.1 Heat Denaturation of Injury Sample AGP (Oligosaccharide 
Preparation) 
 Similarly to monosaccharide preparation of injury AGP samples, there 
was a need within this project to study the arrangements of the monosaccharide 
units (the glycan branching) within the AGP molecule. To accomplish this, acid 
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hydrolysis was not possible; in this instance, there was a need to maintain the 
glycosidic bonds between the monosaccharide molecules so that determination 
of the actual arrangements of the branches could take place. 
 Firstly, there was a need to determine the volume of injury AGP sample 
needed to provide 100µg worth of AGP for oligosaccharide preparation; an 
example of such was shown on page 34. As with monosaccharide preparation, 
should the volume have been more than 100µl, then the sample was dried 
down to completion before being reconstituted in 100µl of HPLC water. Each 
sample was then placed within a fresh aluminium lined 1.5ml glass vial, before 
being placed into the heat block at 100oC for 3 hours. This would denature the 
protein backbone of the AGP molecule, while leaving the monosaccharide 
arrangements within the molecule intact. Once the three hour period was 
complete, addition of 100µl of HPLC water and a light vortex was used to 
encourage re-suspension of the AGP sample; as the heat block had been at 
100oC, it is possible that the majority of AGP sample would have evaporated 
within the glass vial, the addition of HPLC water can help to encourage this re-
suspension. Once re-suspended, each sample was then dried down to 
completion before the next stage of oligosaccharide preparation. 
 
2.2.9.2 Enzyme Digestion of Injury AGP Samples (Oligosaccharide 
Preparation) 
 While heat denaturation denatures the AGP protein molecule, it does not 
separate the desired glycan branches from the protein backbone; this was 
achieved by the addition of PNGase F enzyme. This cleaves the desired glycan 
branches from their five bonding sites on the surface of the AGP protein 
backbone. 
 Firstly, an incubator was set up to allow time to reach the optimum 
temperature of the PNGase F enzyme, which was 37oC. From here, a stock 
solution of PNGase F solution was made; only five units of the enzyme were 
needed for each sample at this stage of the preparation. To accomplish this, 1µl 
of a 500 unit/µl stock of the enzyme was taken and diluted in 99µl of HPLC 
grade water within a fresh eppendorf; this diluted the enzyme, and allowed for 
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1µl of the PNGase F dilution to contain the desired 5 units of enzyme needed 
for digestion of the AGP samples. 
 To each eppendorf of dried down AGP, 10µl of NE G7 Buffer was added, 
along with 10µl of 10% NP-40 buffer, and 79µl of HPLC grade water. The 
mixture was light vortexed to encourage re-suspension of the dried down AGP. 
Finally, 1µl of PNGase F (5 units) from the prepared enzyme dilution was added 
to each eppendorf tube, thus beginning the enzymatic digestion of the AGP. 
Each sample was taken and placed within the prepared incubator at 37oC for 24 
hours. After 24 hours had passed, a further 1µl (5 units) of PNGase dilution was 
added to the solution, before beginning another 24 hour incubation. While this 
incubation was carried out, 300µl of ethanol per sample was transferred into 
fresh eppendorf tubes and placed within the freezer to chill overnight for the 
next step of the preparation. 
 
2.2.9.3 Ethanol Precipitation of Injury AGP Samples (Oligosaccharide 
Preparation) 
 At this stage of the preparation, the PNGase enzyme had cleaved the 
desired AGP glycan branches from the protein backbone; as a result, it was 
necessary to separate the glycan branches from the digested protein molecule. 
This was achieved through precipitation of the injury AGP samples using ice 
cold ethanol and centrifugation. To stop the enzymatic digestion reaction, 300µl 
of ice cold ethanol was added to the reaction mixture; the volume of ethanol 
added should be three times that of the enzymatic solution (in a ratio of 3 parts 
ethanol:1 part enzymatic solution), hence 300µl of ethanol added to 100µl of 
enzyme solution.  
 The resultant 400µl AGP samples were then placed within a freezer at    
-20oC overnight for incubation. After the incubation was complete, the injury 
AGP samples were centrifuged at 14000rpm for 30 minutes within an eppendorf 
centrifuge; this would separate the glycan chains within the ethanol from the 
protein backbone, leaving the protein backbone molecules as a pellet at the 
bottom of the centrifuge. The supernatant was transferred to a fresh eppendorf 
tube, while the pellet was discarded. Each AGP sample was then dried down to 
46 
 
completion using the gyrovap. Once dried down, the samples were then 
reconstituted in 200µl of HPLC grade water before being transferred to fresh 
1.5ml Dionex vials for use within the HPAEC for oligosaccharide analysis. 
 
2.2.9.4 Oligosaccharide Analysis by HPAEC 
 Oligosaccharide analysis by HPAEC utilises the same principle as 
monosaccharide analysis; each glycan branch is separated out on the basis of 
the degree of negative charge within the branches, effectively, separating each 
type of branch out on the basis of size as the isocratic gradient increases, i.e. 
bi-antennary branches will separate off the column first (typically between 20-30 
minutes), tri-antennary branches would be next (30-40 minutes) with tetra-
antennary branches coming off last (40-50 minutes). The specific protocol itself, 
however, is slightly different, in that sodium acetate was also used alongside 
NaOH and HPLC grade water as the mobile phase within this type of 
separation; the length of the separation run itself was also longer (50 minutes) 
to accommodate the retention times of the glycan branches. 
 The newly reconstituted injury AGP samples were placed within the 
autosampler of the HPAEC alongside a commercial AGP standard, and an 
oligosaccharide library as a control to show the HPAEC was working to 
specifications and to allow comparison of injured AGP to “normal AGP”. Once 
complete, samples were kept within the freezer and the necessary 
chromatographs were printed out and used for further analysis. 
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3. Results 
3.1 Monosaccharide Analysis 
3.1.1 Purification Results 
The blood samples from participants with injury used within the project 
were collected via venepuncture, carried out within the University by a qualified 
phlebotomist. The two normal blood samples were received from the NHS 
Blood Transfusion Service. These samples were collected into anti-coagulant 
lined (EDTA) blood tubes before use within the project.  
 It was necessary to remove the red blood cells and most trace proteins 
from within the samples before any further purification could be carried out. This 
was achieved by adding 0.4g of 3350 PolyEthylene Glycol (PEG) per millilitre of 
sample blood. Any molecule under 3350 Daltons in molecular weight was 
precipitated off within the PEG. Each sample was stored in the fridge at 4oC 
overnight, before being spun within the eppendorf centrifuge at 14000rpm for 30 
minutes. Once each sample had been spun for 30 minutes, the clear plasma 
precipitation was collected into a fresh eppendorf tube while the red pellet was 
discarded. This plasma then contained three proteins of similar molecular 
weights; the desired AGP protein (43kDa), alongside albumin (67kDa) and α-
anti-trypsin (AAT) (52kDa), both of which would be removed by low pressure 
chromatography, described within the methods section of this thesis.  An 
example of a complete blue column chromatogram can be found in Figure 5 
below. 
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Figure 5. Blue Column Low Pressure Chromatography Chromatograph 
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Figure 5 shows the transit of a blood sample through the reactive blue 
sepharose filled Bio-rad column. Point 1 shows the addition of elution buffer 
(Blue) to the blue column to achieve column equilibration. Point 2 shows the 
addition of the blood sample to the column, with Point 3 showing the 
appearance of the AGP/AAT mixture passing through the UV detector, and thus 
was the collection point within the project. Point 4 shows the moment at which 
collection was stopped, with all the AGP/AAT having passed through the 
column; at this point description buffer (Blue) was added to the column in order 
to remove the albumin bound to the column, with Point 5 showing the point at 
which column cleaning was completed and blue column purification ended.   
Once blue column purification had been carried out, each AGP/AAT 
sample was dried down to ~2ml of solution before being purified via the action 
of red column purification. The transit of the protein mixture through the column 
was then recorded, this can be found below; 
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Figure 6. Red Column Low Pressure Chromatography Chromatograph 
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Figure 6 shows the transit of an AGP/AAT sample through the reactive 
red agarose filled Bio-rad column. Point 1 shows the addition of elution buffer 
(Red) to the red column to achieve column equilibration. Point 2 shows the 
addition of the AGP/AAT sample to the column, with Point 3 showing the 
appearance of the AGP mixture passing through the UV detector, and thus was 
the point where collection of the sample began. Point 4 shows the point at 
which collection was stopped, with all the AGP sample having passed through 
the column; at this point the cleaning buffer was added to the column in order to 
remove the AAT bound to the column, with Point 5 showing the point at which 
column cleaning was completed and red column purification ended. 
Each sample received for analysis in this project was purified in this 
manner before being further purified via centrifugation to remove NaCl 
molecules which were introduced during the red column purification. Once each 
sample had been purified, they were then read within the spectrophotometer to 
determine the mass of AGP within each sample. Using the above purification 
method, the samples were then found to contain the following masses of AGP 
within them. 
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Sample Name Absorbance at 
280nm 
Concentration of AGP 
within Sample(mg/ml) 
SH001 18/3 2.998 3.450 
GI001 7/6/10 3.000 3.460 
EW001 20/3 0.991 1.143 
LG001 12/9 1.498 1.727 
SH002 7/6/10 0.443 0.511 
WR001 11/16 0.232 0.268 
XX001 ?/? 0.299 0.345 
GI001 7/6/10 Healed 1.127 1.300 
EW001 20/3 Healed 0.274 0.316 
LG001 12/9 Healed 0.632 0.730 
WR001 11/16 Healed 0.458 0.530 
Normal Blood 0.640 0.738 
Table 3. Summary of Concentration of AGP and Absorbance when 
tested at 280nm within Tested Project Samples 
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3.1.2 Monosaccharide Quantification 
Throughout the course of the project, once the monosaccharides within 
the samples had been detected, it was then necessary to quantify the 
monosaccharides found within each tested sample. This was achieved by 
making a monomix solution before making up standard dilutions of the mixture 
(ranging from 0µg-50µg each within 200µl of HPLC water) which were testing 
the samples within the HPAEC, and quantifying each of the monosaccharides 
within each trace over the course of the entire run. Once all the samples had 
been tested, the results for each individual monosaccharide were collated for 
the entire run (i.e. the peak areas seen for fucose throughout the five runs were 
all entered into Excel). Each monosaccharides detected peak area was entered 
into excel and a standard curve for that monosaccharide over time was 
produced, and an equation was given; this equation would allow the further 
determination of a given monosaccharide amount when monosaccharide testing 
of AGP samples was carried out. 
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Graph 2. Standard Curve of Individual Monomix Monosaccharide 
Components 
 
Graph 3. Graph of Peak Area Against Increasing Monomix Component 
Mass (µg) 
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The resultant equations for the above monosaccharide components of the 
Monomix were as follows; 
Fucose: y=28.734 x- 18.769 
Internal Standard: y=33.845 x- 23.666 
Glucosamine: y= 56.962 x- 7.6543 
Galactose: y= 31.482 x- 34.35 
Mannose: y= 14.341 x- 16.616 
Y is representative of the peak area achieved within monosaccharide analysis, 
while x is monosaccharide amount. The equations were then rearranged to 
determine x; 
Fucose: x= (Y+18.769)/28.734 =___µg 
Glucosamine: x= (Y+7.6543)/56.962= ___µg 
Galactose: x= (Y+34.35)/31.482= ___µg 
Mannose: x= (Y+16.616)/14.341= ___µg 
These equations were then used to detect the amounts of the monosaccharides 
detected within the monosaccharide analysis section of this thesis. 
Throughout the course of the investigation, there was an appearance of 
an unknown monosaccharide within the monosaccharide analysis runs of some 
tested samples. It was then necessary to determine the identity of the 
monosaccharide, after which it would be quantified. Due to this monosaccharide 
appearing between galactose and mannose, it was thought that the 
monosaccharide was that of glucose; on account of the similar chemical 
structure between the three molecules.  A monomix run with glucose added to 
the mixture was carried out; glucose was found to appear between the two 
monosaccharides, as it had been within some of the AGP samples! This 
evidence was further compounded when glucose was run through the HPAEC 
on it’s own for comparison, with the sugar coming off 19.9 minutes into the run, 
between the typical retention times for galactose (19.4 minutes) and mannose 
(21.1 minutes).  
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 Now it was necessary to quantify the amount of glucose found within the 
necessary injury samples; the protocol followed was akin to that used to 
quantify the monomix components. Known masses (0µg-50µg) of glucose were 
diluted into 200µl HPLC water solutions before being tested within the HPAEC. 
Once the analysis had been completed, the peak areas of glucose within each 
of the standards were taken and added to excel to create a standard curve for 
glucose, seen over; 
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Graph 4. Standard Curve for Glucose 
 
Graph 5. Peak Area Against Increasing Glucose Mass (µg) 
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The resultant equation for glucose concentration determination was; 
Y= 453.05 x- 239.8 
This equation was then rearranged so that it may be used to determine the 
amount of glucose detected within AGP samples; 
Glucose: x= (Y+ 239.8)/453.05= ___µg 
Using this information, it was then possible to quantify the amounts of glucose 
detected within the necessary samples. 
 
3.1.3 Monosaccharide Results 
 Table 4 shows the monosaccharide composition analysis of all the 
samples, while Table 5 shows the results of monosaccharide analysis in moles 
of monosaccharide per moles of AGP. Table 6 looks at the percentage 
differences in the amounts of individual monosaccharides between the physical 
injury samples and the normal blood sample. Graphs 6-9 show comparisons 
between all tested samples, and the normal blood received for use within the 
study.  
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Monosaccharide Amounts (µg) 
Sample 
Name 
Fucose Glucosamine Galactose Glucose Mannose 
SH001 18/3 0.00 0.14 0.00 0.00 1.30 
GI001 
7/6/10 
0.00 0.17 1.21 0.00 1.18 
EW001 20/3 0.66 0.42 1.11 0.00 1.18 
LG001 12/9 0.66 0.14 1.95 0.00 1.18 
SH002 
7/6/10 
0.70 0.36 1.65 0.55 1.20 
WR001 
11/16 
0.68 0.14 1.72 0.53 1.60 
XX001 ?/? 0.70 0.40 1.66 0.53 1.61 
GI001 
7/6/10 H 
0.00 0.21 1.23 0.00 1.77 
EW001 20/3 
H 
0.66 0.16 1.42 0.53 1.42 
LG001 12/9 
H 
0.66 0.12 1.19 0.00 1.49 
WR001 
11/16 H 
0.68 0.24 1.64 0.53 1.63 
Normal 0.66 0.46 1.60 0.00 1.32 
Table 4. Results of Monosaccharide Analysis on Project Samples (µg) 
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Monosaccharide Amounts (moles of Monosaccharide per mole of 
AGP) 
Sample 
Name 
Fucose Glucosamine Galactose Glucose Mannose 
SH001 
18/3 
0.00 11.17 0.00 0.00 124.08 
GI001 
7/6/10 
0.00 13.56 115.49 0.00 112.63 
EW001 
20/3 
69.14 33.51 105.95 0.00 112.63 
LG001 
12/9 
69.14 11.17 186.13 0.00 112.63 
SH002 
7/6/10 
73.33 28.72 157.49 52.5 114.54 
WR001 
11/16 
71.23 31.91 164.17 50.59 152.72 
XX001 ?/? 73.33 31.91 158.45 50.59 153.67 
GI001 
7/6/10 H 
0.00 16.75 117.4 0.00 168.95 
EW001 
20/3 H 
69.14 12.76 135.54 50.59 135.54 
LG001 
12/9 H 
69.14 9.57 11.58 0.00 142.23 
WR001 
11/16 H 
71.23 19.15 156.54 50.59 155.58 
Normal  69.14 36.7 152.72 0.00 126.99 
Table 5. Monosaccharide Analysis of Project Samples (moles mon/mole AGP) 
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Percentage Differences of Injury Samples against the Normal Blood 
Sample 
 Fucose Glucosamine Galactose Glucose Mannose 
SH001 
18/3 
100% 
decrease 
69.7% 
decrease 
100% 
decrease 
Not 
Present 
1.5% 
decrease    
GI001 
7/6/10 
100% 
decrease 
63% 
decrease 
24.4% 
decrease 
Not 
Present 
10.6% 
decrease 
EW001 
20/3 
No 
Change 
8.7% 
decrease 
30.6% 
decrease 
Not 
Present 
10.6% 
decrease 
LG001 
12/9 
No 
Change 
69.6% 
decrease 
21.9% 
increase 
Not 
Present 
10.6% 
decrease 
SH002 
7/6/10 
6.1% 
increase 
21.7% 
decrease 
3.1% 
increase 
100% 
increase 
9.1% 
decrease 
WR001 
11/16 
3.1% 
increase 
69.6% 
decrease 
7.5% 
increase 
100% 
increase 
21.2% 
increase 
XX001 
?/? 
6.1% 
increase 
13% 
decrease 
3.8% 
increase 
100% 
increase 
22% 
increase 
Table 6. Table of Percentage Differences of Amount of Monosaccharide 
(µg) within Injury Samples Compared Against the Normal Blood Sample 
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Graph 6. Comparison of Monosaccharide Composition of SH001 18/3, 
GI001 7/6/10 and Normal Blood (µg) 
SH001 18/3 showing only two detected monosaccharides out of a possible five 
when compared to the normal sample. There was found to be a 69.7% 
decrease in the levels of glucosamine within SH001 18/3 when compared to the 
normal blood sample, this equates to a 0.3 fold difference between the two 
samples. There was also found to be a 1.5% decrease in the levels of mannose 
within SH001 18/3 against the normal blood sample, this itself equates to a 0.98 
fold difference. GI001 7/6/10 is showing three detected monosaccharides out of 
a possible five when compared to the normal sample. Injury sample is showing 
lower levels of all detected monosaccharides compared to the normal blood 
sample; there was found to be a 63% decrease in the level of glucosamine (a 
0.37 fold difference), a 24.4% decrease in the levels of galactose (a 0.76 fold 
difference), and a 10.6% decrease in the levels of mannose (a 0.89 fold 
difference) against the normal.  
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SH001 18/3 Inj 0 0.14 0 1.3 
Normal Blood 0.66 0.46 1.6 1.32 
GI001 7/6/10 Inj 0 0.17 1.21 1.18 
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Graph 7. Comparison of Monosaccharide Composition of EW001 20/3, 
LG001 12/9 and Normal Blood (µg) 
EW001 20/3 showing all four expected monosaccharides. Both samples are 
showing 0.66µg of fucose. Injury sample is showing an 8.7% decrease in the 
levels of glucosamine (a 0.91 fold difference), a 30.6% decrease in the levels of 
galactose (a 0.69 fold difference) and a 10.6% decrease (a 0.89 fold difference) 
in the levels of mannose when compared to the normal blood sample. LG001 
12/9 showing same level of fucose as that within the normal; sample also 
showing less glucosamine than normal (a 69.6% decrease or a 0.3 fold 
difference). LG001 12/9’s showing more galactose than normal (a 21.9% 
increase or a 1.21 fold difference). Similar to the previous sample, LG001 12/9 
is showing lower levels of mannose when compared to the normal blood 
sample, showing a 10.6% decrease, or a 0.89 fold difference. 
 
 
Fucose Glucosamine Galactose Mannose 
EW001 20/3 Inj 0.66 0.42 1.11 1.18 
Normal Blood 0.66 0.46 1.6 1.32 
LG001 12/9 Inj 0.66 0.14 1.95 1.18 
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Graph 8. Comparison of Monosaccharide Composition of SH002 7/6/10, 
WR001 11/16 and Normal Blood (µg) 
SH002 7/6/10 is showing more fucose than normal sample (an increase of 
6.1%, and a fold difference of 1.1). Injury sample is showing a 21.7% decrease 
in the levels of glucosamine compared to the normal (a 0.78 fold difference). 
Conversely, the injury sample is showing slightly more galactose than normal (a 
3.1% increase or a 1.03 fold difference). SH002 7/6/10 is also showing the 
unexpected appearance of glucose. Injury sample is showing less mannose 
than normal blood (a decrease of 9.1% or a fold difference of 0.91). WR001 
11/16 is showing a 3.1% increase in the levels of fucose when compared to the 
normal sample (a fold difference of 1.03), while showing a decrease of 69.6% in 
glucosamine levels when compared against the normal sample (a fold 
difference of 0.3). The injury sample showed a 7.5% decrease in the levels of 
galactose (a 1.07 fold difference) against the normal blood sample. WR001 
11/16 also possesses glucose; while also possessing a 21.2% increase in 
mannose content against the normal sample (a 1.21 fold difference).  
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SH002 7/6/10 Inj 0.7 0.36 1.65 0.55 1.2 
Normal Blood 0.66 0.46 1.6 0 1.32 
WR001 11/16 Inj 0.68 0.14 1.72 0.53 1.6 
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Graph 9. Comparison of Monosaccharide Composition of XX001 ?/? and 
Normal Blood (µg) 
XX001 ?/? possesses 6.1% more fucose (a 1.1 fold difference) than normal 
sample, while possessing 13% less glucosamine than normal (a fold difference 
of 0.87). The unknown sample possesses 3.8% more galactose than normal 
(1.04 fold difference). The unknown sample is also showing the presence of 
glucose of which is not present in the normal. XX001 ?/? also possesses 22% 
more mannose than the normal blood sample, which is a fold difference of 1.22.  
The following table (Table 7) shows the percentage differences in the amounts 
of monosaccharides from physical injury samples as compared to their 
respective healed samples; graphs (Graphs 10-13) show the comparisons of 
monosaccharide composition between MTB injury samples, and those samples 
received from willing volunteers once they had recovered from their respective 
injuries.  
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Percentage Differences of Injury Samples against their Respective Healed 
Blood Samples 
 Fucose Glucosamine Galactose Glucose Mannose 
GI001 
7/6/10 
No 
Change 
19% 
decrease 
1.6% 
decrease 
Not 
Present 
33.3% 
decrease 
EW001 
20/3 
No 
Change 
65.2% 
increase 
21.8% 
decrease 
100% 
decrease 
16.9% 
decrease 
LG001 
12/9 
No 
Change 
16.7% 
increase 
63.9% 
increase 
Not 
Present 
20.8% 
decrease 
WR001 
11/16 
No 
Change 
41.7% 
increase 
4.7% 
increase 
No 
Change 
1.8% 
decrease 
Table 7. Table of Percentage Differences of Amounts of Monosaccharide 
(µg) within Injury Samples Compared Against their Respective Healed 
Blood Samples 
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Graph 10. Comparison of Monosaccharide Composition of GI001 7/6/10 
Injury and Healed Samples (µg) 
The sample is showing three of the four expected monosaccharides; no fucose 
was detected within the sample. The injury sample is showing 0.17µg of 
glucosamine, 1.21µg of galactose, and 1.18µg of mannose. A follow up sample 
was available from the volunteer once their injury had healed. This sample, 
GI001 7/6/10 Healed, showed the same three monosaccharides that was 
detected within the injury sample. The healed sample contained 0.21µg of 
glucosamine (a 19% decrease within the injured state, and a 0.81 fold 
difference), 1.23µg of galactose (a 1.6% decrease within the injured state, and a 
0.98 fold difference) and 1.77µg of mannose (a 33.3% decrease within the 
injured state, and a 0.66 fold difference); all three monosaccharides have 
decreased in amount between the subject being healthy and becoming injured.  
Fucose Glucosamine Galactose Mannose 
GI001 7/6/10 Inj 0 0.17 1.21 1.18 
GI001 7/6/10 Hea 0 0.21 1.23 1.77 
Normal Blood 0.66 0.46 1.6 1.32 
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Graph 11. Comparison of Monosaccharide Composition of EW001 20/3 
Injury and Healed Samples (µg) 
The sample is showing four out of the four expected monosaccharides; with 
0.66µg of fucose, 0.42µg of glucosamine, 1.11µg of galactose, and 1.18µg of 
mannose being detected within the sample. A healed sample was also available 
from the volunteer, EW001 20/3 Healed. This sample possessed all four 
expected monosaccharides, plus the unexpected appearance of glucose; with 
0.66µg of fucose (no change), 0.16µg of glucosamine (a 65.2% increase within 
the injured state, and a 2.86 fold difference), 1.42µg of galactose (a 21.8% 
decrease within the injured state, and a fold difference of 0.78), and 1.42µg of 
mannose (a 16.9% decrease within the injured state, and a fold difference of 
0.83) being detected; 0.53µg of glucose was also detected within the healed 
sample.  
 
Fucose Glucosamine Galactose Glucose Mannose 
EW001 20/3 Inj 0.66 0.42 1.11 0 1.18 
EW001 20/3 Hea 0.66 0.16 1.42 0.53 1.42 
Normal Blood 0.66 0.46 1.6 0 1.32 
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Graph 12. Comparison of Monosaccharide Composition of LG001 12/9 
Injury and Healed Samples (µg) 
The injury sample shows four of the expected monosaccharides when detected; 
with 0.66µg of fucose, 0.14µg of glucosamine, 1.95µg of galactose, and 1.18µg 
of mannose being detected within the sample. A healed sample, LG001 12/9 
Healed, was also provided with 0.66µg of fucose (no change), 0.12µg of 
glucosamine (a 16.7% increase within the injured state, and a fold difference of 
1.17), 1.19µg of galactose (a 63.9% increase within the injured state, and a 1.64 
fold increase), and 1.49µg of mannose (a 20.8% decrease within the injured 
state, and a 0.79 fold difference).  
 
Fucose Glucosamine Galactose Mannose 
LG001 12/9 Inj 0.66 0.14 1.95 1.18 
LG001 12/9 Hea 0.66 0.12 1.19 1.49 
Normal Blood 0.66 0.46 1.6 1.32 
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Graph 13. Comparison of Monosaccharide Composition of WR001 11/16 
Injury and Healed Samples (µg) 
The sample is showing the four expected monosaccharides and glucose again; 
with 0.68µg of fucose, 0.14µg of glucosamine, 1.72µg of galactose, 1.6µg of 
mannose, and 0.53µg of glucose were detected during HPAEC analysis. The 
volunteer also was able to provide a healed sample for analysis; with 0.68µg of 
fucose (no change), 0.24µg of glucosamine (a 41.7% decrease within the 
injured state, and a 0.58 fold difference), 1.64µg of galactose (a 4.7% increase 
within the injured state, and a 1.05 fold difference), 1.63µg of mannose (a 1.8% 
decrease within the injured state, and a 0.98 fold difference), and 0.53µg of 
glucose (no change).  
Finally, the following table shows the percentage differences in the amount of 
monosaccharide found within physical injury samples when compared to the 
unknown injury sample; graphs 14-16 show the comparison of monosaccharide 
composition between the known injury samples, and the unknown injury sample 
(XX001 ?/?). 
Fucose Glucosamine Galactose Glucose Mannose 
WR001 11/16 Inj 0.68 0.14 1.72 0.53 1.6 
WR001 11/16 Hea 0.68 0.24 1.64 0.53 1.63 
Normal Blood 0.66 0.46 1.6 0 1.32 
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Percentage Differences of Unknown Injury Sample against the Known 
Injury Samples 
 Fucose Glucosamine Galactose Glucose Mannose 
SH001 
18/3 
100% 
increase 
185.7% 
increase 
100% 
increase 
100% 
increase 
23.8% 
increase 
GI001 
7/6/10 
100% 
increase 
135.3% 
increase 
37.2% 
increase 
100% 
increase 
36.4% 
increase 
EW001 
20/3 
6.1% 
increase 
4.8% 
decrease 
49.5% 
increase 
100% 
increase 
36.4% 
decrease 
LG001 
12/9 
6.1% 
increase 
185.7% 
increase 
14.9% 
decrease 
100% 
increase 
36.4% 
increase 
SH002 
7/6/10 
No 
Change 
11.1% 
increase 
0.6% 
increase 
3.6% 
decrease 
34.2% 
increase 
WR001 
11/16 
2.9% 
increase 
185.7% 
increase 
3.5% 
decrease 
No 
Change 
0.6% 
increase 
Table 8. Percentage Differences of Amount of Monosaccharide (µg) within 
Unknown Injury Sample Compared Against the Known Injury Samples 
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Graph 14. Comparison of Monosaccharide Composition between SH001 
18/3, GI001 7/6/10 and XX001 ?/? (µg) 
XX001 ?/? showing the presence of five monosaccharides compared to SH001 
18/3’s two. Despite sharing glucosamine and mannose with XX001 ?/?, SH001 
18/3 showing these monosaccharides at lower levels than the unknown, with 
the unknown possessing 185.7% more glucosamine (a fold difference of 2.86) 
and 23.8% more mannose (a fold difference of 1.24) respectively. XX001 ?/? 
showing the previously unexpected monosaccharide, glucose. Again, the 
unknown is showing five monosaccharides compared to GI001 7/6/10’s three. 
The unknown sample is showing glucosamine (a 135.3% increase against the 
known sample, and a 2.35 fold difference), galactose (a 37.2% increase, and a 
1.37 fold difference) and mannose (a 36.4% increase, and a 1.36 fold 
difference) at higher levels than the general injuries sample. No fucose has 
been detected at all in GI001 7/6/10, while it has in XX001 ?/?. Glucose has 
also been detected within XX001 ?/?. 
  
Fucose Glucosamine Galactose Glucose Mannose 
SH001 18/3 Inj 0 0.14 0 0 1.3 
XX001 ?/? Inj 0.7 0.4 1.66 0.53 1.61 
GI001 7/6/10 Inj 0 0.17 1.21 0 1.18 
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Graph 15. Comparison of Monosaccharide Composition between EW001 
20/3, LG001 12/9 and XX001 ?/? (µg) 
The samples share all four expected monosaccharides, with the unknown also 
showing glucose. There are slight differences in the levels of fucose and 
glucosamine between EW001 20/3 and the unknown; with the unknown injury 
possessing 6.1% more fucose (a fold difference of 1.06) and 4.8% less 
glucosamine (a fold difference of 0.95) than the unknown. More differences are 
apparent within galactose and mannose levels, with XX001 ?/? showing 49.5% 
more galactose (a 1.49 fold difference) and 36.4% more mannose (a 1.36 fold 
difference) than the known sample.  XX001 ?/? showing slightly more fucose 
than has been detected within LG001 12/9 (6.1% more, a 1.06 fold increase), 
this is also apparent when considering glucosamine (185.7% more, and a fold 
difference of 2.86) and mannose (36.4% more, and a fold difference of 1.36) 
levels. However, XX001 ?/? does contain 14.9% less galactose than what has 
been detected within LG001 12/9, a fold difference of 0.85.  
 
Fucose Glucosamine Galactose Glucose Mannose 
EW001 20/3 Inj 0.66 0.42 1.11 0 1.18 
XX001 ?/? Inj 0.7 0.4 1.66 0.53 1.61 
LG001 12/9 Inj 0.66 0.14 1.95 0 1.18 
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Graph 16. Comparison of Monosaccharide Composition between SH002 
7/6/10, WR001 11/16 and XX001 ?/? (µg) 
All samples contain the four expected monosaccharides; they also contain the 
unexpected presence of glucose. The same level of fucose is detected within 
the unknown and SH002 7/6/10. There are differences in the levels of 
glucosamine and galactose between the two samples, with 11.1% more 
glucosamine detected within the unknown (a fold difference of 1.11) and 0.6% 
more (a fold difference of 1.01) being detected within XX001 ?/?. The unknown 
possesses 3.6% less glucose than SH002 7/6/10; a resulting fold difference of 
0.96. The unknown possesses 34.2% more mannose than SH002 7/6/10 (a fold 
difference of 1.34). Differences are seen between the unknown and WR001 
11/16 with regards to fucose level (with the unknown possessing 2.9% more, a 
fold difference of 1.03), and galactose levels (with the unknown showing 3.5% 
less galactose, a fold difference of 0.96). There was a slight 0.6% increase in 
the level of mannose within the unknown compared to WR001 11/16 (a fold 
difference of 1.01). The biggest difference between these two samples is in their 
glucosamine levels, as XX001 ?/? shows 185.7% more of the monosaccharide 
compared to WR001 11/16; this is a fold difference of 2.86.   
 
Fucose Glucosamine Galactose Glucose Mannose 
SH002 7/6/10 Inj 0.7 0.36 1.65 0.55 1.2 
XX001 ?/? Inj 0.7 0.4 1.66 0.53 1.61 
WR001 11/16 Inj 0.68 0.14 1.72 0.53 1.6 
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3.2 Oligosaccharide Analysis 
3.2.1 Oligosaccharide Results 
The following graphs represent the results of the oligosaccharide analysis 
carried out on MTB injury samples within the HPAEC.  In addition to these 
samples, a control sample was run through the HPAEC to act as a reference for 
each of the injury samples. This N-linked library contained oligosaccharide 
structures within to provide a reference of oligosaccharide structures in vivo, 
which could then be further used to highlight differences within the structures 
within the tested samples within this project. Two characteristics that will be 
analyzed within these results are the peak elution of the tested samples (how 
high the peaks reach) and the peak activity of the injury samples (how many 
peaks appear within an area of the graph, whether they appear to increase or 
decrease in complexity), these will then form the basis of comparisons between 
samples. Graph 17 shows the N-linked library when analysed on it’s own within 
the HPAEC. 
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Graph 17. Oligosaccharide Analysis Chromatogram of N-Linked Library 
The N-linked library when analysed on its own was shown to contain relatively 
small peaks within the bi sialylated area; with three being countable. The 
sample produced two very large peaks within the tri sialylated area (out of nine 
peaks) and five large (out of eleven) peaks within the tetra sialylated area. 
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Graph 18. Oligosaccharide Analysis Chromatogram of SH001 18/3 and 
GI001 7/6/10. 
SH001 18/3 showing one visible peak within the “bi” sialylated area (20-30 
mins), four peaks within the “tri” area (30-40 mins), and one peak within the 
“tetra” sialylated area (40-50 mins). GI001 7/6/10 is showing one definite peak 
within the bi sialylated area, five peaks within the tri sialylated area (two peaks 
being larger than the others), and two peaks within the tetra sialylated area.  
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Graph 19. Oligosaccharide Analysis Chromatogram of EW001 20/3 and 
LG001 12/9 
EW001 20/3  possesses one very large bi peak, followed by three smaller 
peaks, five small and one large peak within the tri sialylated, and eight peaks 
seen within the tetra sialylated area (one of these peaks being particularly 
prominent). LG001 12/9 showed a small number of definitive peaks, with two of 
the most prominent peaks coming within the bi sialylated area of the 
chromatogram. Following this, a few very small peaks can be seen within the tri 
and tetra sialylated areas. 
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Graph 20. Oligosaccharide Analysis Chromatogram of SH002 7/6/10 and 
WR001 11/16. 
SH002 7/6/10 possesses two small peaks that can be seen within the bi 
sialylated area, two very prominent peaks can be seen within the tri sialylated 
area, with three more peaks within the tetra sialylated area and a small double 
peak coming off towards the end of the tetra portion of the graph. WR001 11/16 
is showing a small number of very small peaks within the bi sialylated area. Two 
prominent peaks appear within the tri sialylated area. There are four peaks that 
appear within the tetra sialylated area. 
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Graph 21. Oligosaccharide Analysis Chromatogram of XX001 ?/?.  
XX001 ?/? showing three small peaks within the bi sialylated area. Five peaks 
appear within the tri sialylated area of XX001 ?/?. Finally, three large peaks are 
present within XX001 ?/?’s tetra sialylated area. A small double peak also came 
off within the tetra portion of XX001 ?/?. 
 Further chromatograms show the samples that were acquired for the 
project from previous project volunteers who were able and willing to provide a 
second sample once they had healed from their injuries; allowing this project a 
reference point of comparison within the individual of their AGP glycosylation 
patterns between an injured state and a healed state.  
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Graph 22. Oligosaccharide Analysis Chromatogram of GI001 7/6/10 and 
EW001 20/3 Healed Samples. 
Within this graph, there are two small peaks within the bi area of GI001 7/6/10 
H. Two more peaks appear within the tri area of the sample. There are a further 
two peaks within the tetra area of the sample. There are two small bi peaks 
within the bi area of EW001 20/3 H. There are also five tri branches and a 
further eight peaks are seen within the tetra areas of the sample. 
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Graph 23. Oligosaccharide Analysis of LG001 12/9 and WR001 11/16 
Healed Samples. 
LG001 12/9 Healed sample possesses three small peaks can be seen within 
the bi sialylated area. Two small peaks can be seen within the tri area while five 
small peaks can be seen within the tetra areas of the sample.WR001 11/16 
Healed sample; the sample possessing three countable small peaks coming off 
within the bi sialylated area within the sample, however, they are slight. There is 
one very slight peak within the tri peak area of the chromatogram. There are 
also three definite tetra peaks within the sample. 
Graphs 24-27 show the injury samples when compared to the N-linked library 
(N-lib).  
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Graph 24. Comparison between SH001 18/3, GI001 7/6/10 and N-Linked 
Library Oligo Chromatograms. 
N-Lib is showing clear peak activity as opposed to the peaks within SH001 18/3 
and GI001 7/6/10. Compared to the N-Lib, SH001 18/3 is eluting bi-sialylated 
peaks to a higher degree, the same is true for GI001 7/6/10, both coming just 
under 5nC. There is a decrease in peak activity within tri-sialylated area of the 
graph for both injury samples, with two N-Lib peaks eluting to a higher degree. 
The peaks within the tetra-sialylated area of the injury samples then elute to a 
higher degree within both samples, both coming in just under 20nC, however, 
the peaks appear to show decreasing activity compared to the N-Lib, which 
produced five clear peaks compared to SH001 18/3’s one peak, and GI001 
7/6/10’s two peaks.  
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Graph 25. Comparison between EW001 20/3, LG001 12/9 and N-Linked 
Library Oligo Chromatograms. 
Both injury samples are showing an increased elution and peak activity within 
the bi-sialylated area of the chromatograph when compared to the N-Lib. 
However, both samples then show a decrease in peak elution and peak activity 
in both of the tri and tetra-sialylated areas of the chromatograph when 
compared to the N-Lib. Very different from the N-Lib chromatogram.  
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Graph 26. Comparison between SH002 7/6/10, WR001 11/16 and N-Linked 
Library Oligo Chromatograms 
Both injury samples are showing an increase in peak elution within the bi-
sialylated area of the chromatogram when compared to the N-Lib, however, 
both injury samples also show a decrease in peak activity within the same area 
of the chromatogram. Both injury samples then show a decrease in peak elution 
and peak activity when compared to the N-Lib within the tri-sialylated areas of 
the graph. SH002 7/6/10 would then also go on to show a decrease in peak 
elution and activity within the tetra-sialylated area also, while WR001 11/16 
would show a decrease in peak elution compared to the N-Lib, WR001 11/16 
would also show an increase in peak activity.  
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Graph 27. Comparison between XX001 ?/? and N-Linked Library Oligo 
Chromatograms. 
When compared to the N-Lib, the unknown would show an increase in peak 
elution and activity within the bi-sialylated areas of the chromatogram. The 
unknown would also then show an increase in tri-sialylated peak elution, while 
exhibiting a decrease in tri-sialylated peak activity compared to the N-Lib. 
Finally, XX001 ?/? would also show a decrease in tetra-sialylated peak elution 
when compared to the N-Lib, however, it would also show an increase in peak 
activity. 
Following on from these comparisons, due to the procurement of blood samples 
from those who had healed from their injuries, it was also possible to analyze 
these healed blood samples within the HPAEC. These chromatograms could 
then be compared to those gathered from their injury samples to assess any 
potential change of AGP glycosylation patterns within the individual and to 
measure the extent of these changes when compared to the healed samples; 
with the injury being the “Injured” state, and the healed sample being the 
“Resting” state; this was due to the limitations of the project. Graphs 28-31 
show the oligo chromatogram comparisons of injury samples against their 
healed sample counterparts. 
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Graph 28. Comparison between GI001 7/6/10 Injury and Healed Sample 
Oligo Chromatograms. 
The two samples are showing a very obvious difference from each other. As 
previously mentioned, peak activity and peak elution has increased over all 
fields of branching when the healed and injury sample are compared against 
one another. This certainly shows an obvious change has taken place within the 
AGP of the two samples. The four peaks within the healed sample 
chromatogram arguably share retention times with four of the corresponding 
peaks within the injury sample. This may possibly be an indication of the 
individual being in the process of recovering from their injury; this may show the 
possibility of AGP glycosylation patterns being used as a potential biomarker for 
the recovery from sports injury. 
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Graph 29. Comparison between EW001 20/3 Injury and Healed Sample 
Oligo Chromatograms. 
The biggest difference between the two samples here is the peak height; the 
chromatograms sit on top of each other. Peak elution has decreased within the 
injury sample from the healed sample. When considering peak activity there 
appears to be very little difference between the two samples throughout the tri- 
and tetra-sialylated branching areas, however, it could be argued, due to the 
presence of a larger peak within the bi-sialylated area of the injury sample, that 
there has been an increase in bi-sialylated activity within the injury sample. 
 
 
-2 
-1 
0 
1 
2 
3 
4 
5 
6 
7 
8 
15 25 35 45 55 
n
C
 
Time (mins) 
Oligo Comparison of EW001 20/3 Injury and 
Healed Samples 
EW001 20/3 Inj 
EW001 20/3 Healed 
Bi Sialylated 
Tri Sialylated 
Tetra Sialylated 
89 
 
 
Graph 30. Comparison between LG001 12/9 Injury and Healed Sample 
Oligo Chromatograms. 
There has been an increase in bi-sialylated peak elution and peak activity within 
the injury sample, due to the presence of two large peaks within the bi-area of 
the graph that are not present within the healed sample. Peak elution within the 
injury sample then falls below the healed sample within the tri- and tetra-
sialylated areas of the chromatograph. However, peak activities within these 
areas of the injury sample appear to have increased when compared to the 
healed sample. 
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Graph 31. Comparison between WR001 11/16 Injury and Healed Sample 
Oligo Chromatograms. 
Peak elution has increased within the injury sample when compared to the 
healed sample, with bi-sialylated peaks seeing a slight increase and tri- and 
tetra-sialylated peaks showing a much more obvious increase. Peak activity has 
also increased between the two samples. Again, 10-20 minutes showing a slight 
increased in bi-sialylated peak activity, there being a dramatic increase in tri- 
and tetra-sialylated peaks from 20 minutes and onward. The evidence is 
suggesting that the injury was having an effect on the glycosylation patterns of 
the AGP within the volunteer at the time of the injury blood draw. 
 Finally, the following chromatograms show the differences in 
oligosaccharide composition between the injury samples, and the unknown 
sample (XX001 ?/?) in order to determine the diagnostic potential of AGP 
glycosylation patterns. Graphs 32-34 show the known injury samples when 
compared to the unknown injury sample. 
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Graph 32. Comparison between SH001 18/3, GI001 7/6/10 and XX001 ?/? 
Oligo Chromatograms. 
SH001 18/3 and GI001 7/6/10 show an increase in both peak activity and 
elution within the bi-sialylated branching area. The two injury samples then 
show a decreasing level of tri- and tetra-sialylated branching when compared to 
the unknown. The overall peak elution of SH001 18/3 is higher than that within 
XX001 ?/?,however, aside from bi-sialylated branching, there is a decrease in 
tri- and tetra-sialylated peak activity when comparing SH001 18/3 to the 
unknown. Based on a qualitative examination, it does not appear that SH001 
18/3 and the unknown could be the same injury. When considering GI001 
7/6/10 and the unknown, based on a qualitative examination, it does not appear 
that the two injuries could be the same. 
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Graph 33. Comparison between EW001 20/3, LG001 12/9 and XX001 ?/? 
Oligo Chromatograms. 
When comparing EW001 20/3 and the unknown injury sample, it is interesting 
to note that both samples do look similar in terms of peak shape and retention 
time. However, EW001 20/3 does look to possess a slight decrease in peak 
activity for all branching types. EW001 20/3 does possess an increase in bi-
sialylated peak elution than the unknown sample, while there is a decrease in 
the levels of tri- and tetra-sialylated peaks eluted within EW001 20/3. Based on 
this evidence, it is possible that the unknown injury may be that of an elbow 
injury. Peak elution and activity for the most part has decreased within LG001 
12/9 compared to the unknown, with decreases being seen in tri- and tetra-
sialylated peak elution within the known injury. However, there appears to be an 
increase in bi-sialylated peak elution and peak activity within LG001 12/9 when 
compared to the unknown. Based on this evidence, it is unlikely that the 
unknown injury sample is that of a leg injury. 
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Graph 34. Comparison between SH002 7/6/10, WR001 11/16 and XX001 ?/? 
Oligo Chromatograms. 
SH002 7/6/10 and the unknown appear to share retention times, to the point of 
sitting on top of one another. There is a decrease in peak elution across all 
branching types within SH002 7/6/10 compared to the unknown sample. Based 
on this evidence, it is fully possible that SH002 7/6/10 and XX001 ?/? may be 
that of the same injury type (a shoulder injury). Again, when comparing WR001 
11/16 to the unknown, there are minor differences. Peak elution within WR001 
11/16 has decreased across all branching types compared to the unknown. 
Peak activity appears to show no major changes when comparing WR001 
11/16 to the unknown, apart from a definite increase in tetra-sialylated peak 
activity within WR001 11/16. Again, there are very obvious similarities between 
the two samples here. Both samples are very close together in peak height, with 
the unknown edging out the known injury sample just slightly. However, the 
biggest difference here is that the peaks within WR001 11/16 appear to be 
coming off slightly earlier than those within the unknown sample. Aside from 
this, peak shape appears to be similar, including a small double peak within the 
tetra-sialylated area of the chromatogram of both samples. Based on this 
evidence, it is also possible that XX001 ?/? may be that of a wrist injury, with 
there being some strong evidence to suggest so. 
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3.3 Statistical Analysis of Results 
Due to the relatively small sample size within this project and the possibility of 
missing/extra monosaccharides, statistical analysis of the sample group was 
limited. However, a small degree of statistical analysis was carried out using 
one sample t tests.  
First of all, known injury samples were compared against the Normal blood 
sample. It was necessary to determine if the collected injury samples were 
significantly different from the Normal blood sample. As such, the collected 
monosaccharide means were compared against the null “hypothesis” or the 
mean of the Normal blood sample. A comparison of the monosaccharide means 
of SH001 18/3, GI001 7/6/10, EW001 20/3, and LG001 12/9 was carried out 
against a four monosaccharide averaged Normal sample; the resulting P value 
(two-tailed)= 0.1082, as such there were no significant differences of injury 
samples against the Normal at a statistical level.  A comparison of the 
monosaccharide means of SH002 7/6/10, WR001 11/16 and XX001 ?/? was 
carried out against a five monosaccharide averaged Normal sample; the 
resulting  P value (two tailed)= 0.0418, as such these injury samples were found 
to be significantly different from the Normal. 
A comparison of injury samples against their respective healed samples could 
not be carried out within this study, as such a comparison of the healed 
samples against the Normal sample was carried out statistically instead. For the 
first comparison, the monosaccharide means of GI001 7/6/10 H, and LG001 
12/9 were compared out against a four monosaccharide averaged Normal 
sample; the resulting P value (two tailed)= 0.1257, as such, these two healed 
samples were not significantly different from the Normal. Furthermore, the 
monosaccharide means of EW001 20/3 H, and WR001 11/16 H were compared 
against a five monosaccharide averaged Normal sample; the P value (two 
tailed)= 0.3556, these two samples were not significantly different from the 
Normal also. 
Finally, it was necessary to determine the statistical significance of the 
monosaccharide means of the known injury samples against the unknown injury 
sample. A comparison of the monosaccharide means of SH001 18/3, GI001 
7/6/10, EW001 20/3, LG001 12/9, SH002 7/6/10, and WR001 11/16 (all 
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averaged for five monosaccharides) against the five monosaccharide mean of 
the unknown sample to determine if the known injury samples as a whole were 
significantly different from the unknown; the P value (two tailed)= 0.0301, which 
means the known injury samples are significantly different from the unknown 
injury sample. However, a further comparison was carried out to determine if 
there were any significant differences between the SH002 7/6/10 and WR001 
11/16 against the unknown injury sample, due to the similarities between these 
three samples at the monosaccharide and oligosaccharide level; the P value 
(two tailed)= 0.1772, meaning that the known injury samples were not 
significantly different from the unknown injury sample. 
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4. Discussion 
 The main aims within this project were three fold. First, it was necessary 
to determine whether or not an Acute Phase Response initiated by a physical 
injury would in fact alter the glycosylation patterns of the AGP molecule; should 
this aim have proved successful, then this would form the basis of the other 
aims within the project. These were to determine whether or not different types 
of injury produce different glycosylation patterns within AGP, and whether or not 
AGP glycosylation patterns can be used to diagnose a physical injury.  
 Within this project, injury samples from mountain biking accidents were 
selected for use within the project due to the high speed and high risk of injury 
associated from the sport, as well as the profile that Edinburgh Napier 
University possesses within the mountain biking community. While the APR is 
activated by bacterial infection (Gupta et al., 2010), disease (Poland et al., 
2001), viral infection, strenuous exercise, and physical injury (Kushner and 
Rzewnicki, 1994), and with AGP glycosylation pattern having been affected by 
various different disease types (Gallacher, 2009, Anderson, 2002), up till now 
no studies have been carried out into the effects of physical injury on the 
glycosylation patterns of AGP; although, it has been suggested by Goldberger 
et al., (1987) and Kageyama et al., (1985) that there is a limited linear 
relationship between the severity of the injury suffered and the degree of 
plasma protein expression. The fundamental hypothesis of this project is to 
determine whether or not a physical injury induced APR will affect AGP 
glycosylation patterns in the same way.  
  When considering monosaccharide analysis, the level of difference 
between the tested samples and the normal sample was minute in the 
microgram level. The normal blood sample was found to contain 0.66µg of 
fucose, 0.46µg of glucosamine, 1.6µg of galactose and 1.32µg of mannose; this 
would be considered the “normal” glycosylation composition for the general 
population within this project. At the monosaccharide level, there is no injury 
sample that matches the normal blood sample exactly. The biggest difference 
between an injury sample and the normal sample is that of SH001 18/3, in 
which only two of the expected monosaccharides, glucosamine and mannose, 
were detected within SH001 18/3, while all four monosaccharides were found 
within the normal blood sample. It should also be noted that of the two detected 
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monosaccharides, there was a 0.3 fold decrease of glucosamine within SH001 
18/3 compared to the normal, while there was a 0.98 fold decrease in mannose 
within the SH001 18/3. A similar scenario had appeared when GI001 7/6/10 
was tested, in which only three of the expected monosaccharides (Glucosamine 
at 0.17µg, Galactose at 1.21µg, and Mannose at 1.18µg) were found within the 
sample when compared to the normal blood sample; these sugars when 
compared to their respective levels within the normal blood sample were found 
to be 0.37 fold, a 0.76 fold and 0.89 fold decreases respectively. What is 
interesting to note, is that these two samples were found to contain the highest 
absorbance under 280nm when tested within a spectrophotometer, and as 
such, were calculated to contain the highest concentration of AGP within them. 
When considering this evidence, the levels of glucosamine and mannose within 
SH001 18/3 were found to be no higher than some other samples which 
possessed lower absorbencies and were calculated to contain less AGP than 
either SH001 18/3 and GI001 7/6/10. As such, it may be possible that there was 
a contamination issue within those two samples which affected the resulting 
chromatographs.  
 With regards to monosaccharide analysis, most samples showed some 
differences when compared to the normal blood sample; in fact, most samples, 
apart from SH001 18/3, GI001 7/6/10 and GI001 7/6/10 Healed, showed the 
expected four monosaccharides present within the monomix solution. As 
previously stated, the differences between the tested samples and the normal 
blood sample were minute; with fucose showing the most consistency of all the 
monosaccharides with a 0.04µg range of values within all of the samples it was 
detected within. This is not consistent with the evidence seen within Gallacher’s 
study (2009), in which hyperfucosylation was seen as the severity of the cancer 
observed was increased. It was also seen within the statistical analysis section 
of the thesis, that there are no statistical differences when comparing the 
monosaccharide means of SH001 18/3, GI001 7/6/10, EW001 20/3, and LG001 
12/9 against the Normal blood sample, however, differences have been seen at 
the monosaccharide and oligosaccharide level. Furthermore, when comparing 
SH002 7/6/10, WR001 11/16 and the unknown against the Normal blood 
sample, statistically significant differences were observed. The 
monosaccharides glucosamine, galactose and mannose showed a greater 
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variation in the samples in which they were detected; with a range of 0.12µg 
(LG001 12/9 Healed) to 0.46µg (normal blood) for glucosamine, 1.19µg (EW001 
20/3) to 1.95µg (LG001 12/9) for galactose, and 1.18µg (three samples) to 
1.77µg of mannose (GI001 7/6/10). Perhaps the biggest difference that some 
samples possessed was that of the presence of the unexpected 
monosaccharide glucose. This sugar was detected in three injury samples and 
two healed samples, out of 12 samples tested (42%) within the HPAEC. It’s 
presence within monosaccharide testing was unexpected, as glucose is 
normally removed in the AGP glycosylation pattern building process, thus, it 
was not found within the normal blood sample, and the majority of the collected 
samples for the project. Therefore, the presence of glucose may then show an 
obvious effect that the physical injury has had on the volunteer’s glycosylation 
patterns. The presence of unexpected monosaccharides is not uncommon, in 
both Gallacher’s (2009) and Anderson’s (2002) studies, the monosaccharide 
GalNAc was detected within the more aggressive forms of their respective 
diseases, suggesting that the presence of GalNAc was as a result of the breast 
cancer and the liver diseases experienced by the individuals within each study. 
It is then possible that the presence of glucose within the samples within this 
study is as a result of the injuries suffered by the volunteers. However, it should 
be noted that the level in which glucose was found in each of the tested 
samples proved to be fairly consistent, with one sample (SH002 7/6/10) 
containing 0.55µg of the carbohydrate, and the other four glucose containing 
samples showing 0.53µg of the carbohydrate.  
 When considering a comparison between the tested injury samples and 
their respective healed counterparts, subtle differences emerged. For example, 
the biggest difference between the two samples relating to GI001 7/6/10 (seen 
within Graph 10), was that of the level of mannose detected; with 1.18µg 
detected within the injury, and 1.77µg detected when healed, resulting in a 0.66 
fold decrease when injured. No fucose was detected in either sample, however, 
each detected monosaccharide was found to decrease within the volunteer 
when they were injured. When the results of EW001 20/3 are considered 
(Graph 11), no change was detected in fucose amongst EW002 20/3 injury, 
healed and the normal blood sample. While the levels of galactose and 
mannose decreased (by 0.78 fold and 0.83 fold respectively) when the 
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volunteer was injured, their level of glucosamine increased by 2.86 fold. There 
was also no change in the levels of fucose when LG001 12/9 injury and healed 
(Graph 12), when compared to the normal blood sample. While the volunteers 
levels of mannose decreased by 0.79 fold once injured, their levels of 
glucosamine and galactose increased, by 1.17 fold and 1.64 fold respectively. 
And finally, when considering WR001 11/16 injury and healed samples (Graph 
13), and comparing them to the normal blood sample, it was seen that the level 
of mannose had once again, albeit subtly this time, decreased by 0.98 fold 
when the volunteer became injured, from 1.63µg within the healed sample 
1.6µg within the injury sample; their level of fucose (0.68µg) had also been 
minutely higher than that of the normal at 0.66µg; this level did not alter when 
the injury had occurred. The volunteer’s sample also showed the presence of 
glucose within their injury and healed samples, however, this level did not 
change over the course of testing, staying at 0.53µg. The volunteer’s levels of 
glucosamine would also decrease by 0.1µg from 0.24µg to 0.14µg (a fold 
difference of 0.58) once the injury had taken place (while still being lower than 
the level within the normal sample at 0.46µg), and their level of galactose would 
increase by 0.08µg from 1.64µg to 1.72µg (a fold difference of 1.05) as the 
injury had healed; while still being higher than the normal blood sample. 
Perhaps the biggest link between these four samples, is that after the injuries 
had taken place, their levels of mannose would decrease to levels that were 
lower than those seen within the healed samples themselves. This perhaps 
shows that mannose levels decrease when an individual is injured; the level of 
this decrease would also be dependant on the individual as well. The stability of 
fucose levels throughout the testing period suggest that fucose levels may not 
be affected by injury induced APR, as previous studies have shown fucose 
levels to change dramatically when the APR is induced, particularly when the 
APR is induced by disease. Fujimura et al., (2008) showed fucose levels to 
increase when an individual was suffering from prostate cancer, while invasive 
breast cancer samples (Gallacher, 2009) and hepatitis samples (Anderson, 
2002) have also shown fucose levels to increase within those suffering from 
these conditions. Progression from hepatitis to cirrhosis infections have also 
shown fucose levels to decrease over time (Anderson, 2002). The evidence of 
the stability of fucose levels in this study is in contradiction to evidence 
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presented by Higai et al., (2005), who found that levels of fucose increased 
within those suffering from acute inflammation. However, Higai’s study used 
AGP collected from those experiencing acute inflammatory states brought on by 
disease, not physical injury. The evidence presented in the present study 
suggests that fucose may not be affected by physical injury induced immune 
responses. 
 Moving onto oligosaccharide analysis, it is easier to see that a difference 
has taken place within the tested AGP samples. As previously noted, the first 
aim of this project was to determine whether or not a physical injury induced 
APR would affect AGP glycosylation pattern by analyzing the change in the 
complexity of the profile produced by an injury sample when compared against 
the normal, a healed sample, or the unknown. Change in complexity is defined 
as being either the increase or decrease of a samples peak elution (peak 
height) and/or peak activity (number of peaks produced). While it may not be 
obvious at first glance to determine whether or not a change as taken place 
when looking at the monosaccharide composition of the AGP samples, it is 
much easier to determine if a change has taken place when looking at the 
oligosaccharide composition of the molecule. In fact, when compared to the N-
linked library (Graph 14), there is no tested sample that matches the line 
produced when the N-Lib was tested. Every sample is showing an obvious 
difference from that of the N-Lib. For example, when compared to the N-Lib, 
EW001 20/3 and LG001 12/9 (Graph 22) show far smaller peak heights, 
possessing no shared peak shapes or retention times with the N-lib. 
However, what is also interesting to note is the difference at the 
oligosaccharide level between those injury samples from which there is a 
healed sample available for testing.  When compared against each other, the 
two samples do not share peak elution or complexity and only share peak 
retention times for a small number of peaks. This evidence is seen again when 
comparing the two samples relating to WR001 11/16 (Graph 28); again, peak 
elution and complexity are not shared between the two samples and few peak 
retention times are shared. This evidence is supported by Anderson’s study 
(2002), Gallacher’s study (2009) and Behan’s study (2010), where the tested 
samples have the potential to have little in common with the collected normal 
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samples. This shows that there is potential for injury and healed samples to be 
very different at the oligosaccharide level.  
 
However, it should also be noted, that the evidence provided by these 
differences may be limited, as seen with EW001 20/3 (Graph 26) and LG001 
12/9 (Graph 27). EW001 20/3 paints a different picture here; peak elution is 
again the difference that separates the injury and healed samples, in addition to 
a solitary peak within the injury sample that is higher than others detected within 
the healed sample; these samples do share a large degree of peak retention 
times and shape, showing that the two samples did not possess many 
differences. These similarities somewhat continue when looking at LG001 12/9. 
Again, the two samples can be separated by peak height, however, as opposed 
to what was seen in EW001 20/3, the differences in peak height are a bit more 
evenly distributed, with both samples showing peak heights that are higher than 
the other sample at varying points of the chromatograph i.e. the injury sample 
possesses higher peak heights within the bi-sialylated area of the 
chromatograph, and the healed sample possessing higher peak heights within 
the tetra-sialylated area. However, there appears to be an increase in the levels 
of peak activity within the injury sample when compared to its respective healed 
sample showing that differences between the two samples are present, if not 
obvious at first. The evidence provided by these two volunteers suggests that 
oligosaccharide level differences between injury and healed samples may be 
limited. It should be noted that patterns possessing similarities to this degree 
were not seen in Anderson’s (2002), Gallacher’s (2009) or Behan’s studies 
(2010). However, this study has also had an opportunity to analyze AGP 
collected from those who had recovered from their injuries, allowing a 
perspective within this project that other studies have not had; understandably 
due to the severity of the conditions that were being analyzed, the ability to 
acquire a healed blood sample from volunteers once they had healed may not 
have been possible. Any similarities within injury and their respective healed 
samples could then be as a result of the two samples having come from the 
same person. 
Previous studies, such as that carried out by Gallacher (2009), show a 
correlation between the levels of galactose, a main component of the branches 
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of AGP, and the complexity (changes in peak elution and peak activity) of the 
branches. Within this project, this correlation was seen to a large degree. When 
comparing the injury samples to the normal blood sample, a correlation was 
seen between the levels of galactose and the complexity of the branching 
patterns at the oligosaccharide levels within six of the seven injury samples. A 
decrease in the level of galactose was found to correlate with a decrease in the 
complexity of the branching patterns, while an increase in the level of galactose 
was found to correlate with an increase in the complexity of the branching 
patterns. Previous studies, such as that by Anderson (2002), and Fournier et 
al., (2000), have found the level of fucose to be related to the degree of 
branching at the oligosaccharide level, with an increasing presence of fucose 
suggesting a reduction in the number of bi-sialylated glycans, however, the 
evidence seen within this study does not support these conclusions. Higai et al., 
(2005), found the level of fucose and degree of branching to be independent of 
each other, which was seen within this project. Only LG001 12/9 (seen in Graph 
4 and Graph 16), in which it’s levels of galactose would suggest an increasingly 
complex branching pattern, differed from this evidence; it’s oligosaccharide 
branching pattern would show a less complex branching chain. This correlation 
between the levels of galactose and the complexity of the branching patterns 
was seen again when comparing the monosaccharide composition and 
oligosaccharide branching patterns of the injury samples and those with healed 
samples. In this case, three out of four of the sample sets would support this 
theory, with the levels of galactose in these sample sets suggesting a change in 
complexity of the branching patterns. 
The slight decrease in the level of galactose between GI001 7/6/10 Healed 
and GI001 7/6/10 Injured would suggest a slight decrease in the complexity of 
the branching patterns, however, when the volunteer was injured, their 
oligosaccharide branching pattern became more complex, i.e. the pattern 
produced by the injury sample possessed a higher peak activity and peak 
elution than the sample taken once the volunteer had healed.  
In summary, it was seen throughout the project testing, that the majority of 
injuries produced an effect on the AGP contained within their samples. By 
testing at the monosaccharide levels, the carbohydrates that make up each 
samples respective AGP have been determined and quantified. These 
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carbohydrates were then compared to the gathered normal blood sample for 
this project, and the healed samples that have been provided. While any 
detected differences have been minute, an effect on the AGP, presumably as a 
result of the APR from the injury, has been established. Taking this evidence in 
conjunction with the oligosaccharide evidence of all the samples gathered also, 
shows even further than an effect on the glycosylation patterns of AGP has 
taken place. Kushner and Mackiewicz (1987) suggest that the qualitative 
patterns of APPs (of which AGP is included) are not influenced to a significant 
degree by the type of injury sustained, this contradicts evidence found within 
this study. This change can be further established and quantified when 
observing the levels of galactose within the injured and healed samples. Based 
on the findings within the scope of this project, the findings at this point may be 
limited, however, this work can then be used as the basis for further research 
into the effect that physical injury has on the glycosylation pattern production of 
AGP.  
It could also be argued that the small scope of the study (seven injury 
samples, four healed samples, and a normal blood sample), could have been a 
limiting factor within this study, and arguably, more samples could have added 
more information to this study. However, it should also be noted that it could 
take one month and over to purify a blood sample from venepuncture to 
analysis of the results within the HPAEC. As a result, the number of collected 
samples gathered within the project was ideal for the time frame of this project. 
Should further research within this area be carried out in the future, a longer 
timeframe would allow a higher sample count to be analyzed. The single sport 
of choice may have also been a limiting factor; a wider approach to sport choice 
would also presumably increase the chances for injury. However, by focusing 
on one sport, this study has managed to gather important evidence on the 
relationship between AGP and sports injury that can act as a foundation for 
further project research where a wider sports range can be used within the 
study. Finally, the Beer Lambert Law was used to determine the concentration 
of AGP within the collected injury sample. While in the majority of cases the 
Beer Lambert Law can be used to successfully determine the concentration of 
AGP and other solutions, the Beer Lambert Law also has its limitations; high 
concentrations can cause deviations in absorption coefficients due to the 
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interactions of the molecules at close proximity. This could potentially explain 
the two anomalous results (SH001 18/3 and GI001 7/6/10), where these results 
produced very high absorbance values for (apparently) a low concentration of 
AGP, and as such, the limitations of the Beer Lambert Law should be known 
when using the technique.   
 Following on from the first aim of the project, it was then necessary to 
determine whether or not different injury types would then produce an individual 
effect on the glycosylation patterns of AGP. As previously stated, the ability to 
determine a difference in a sample’s AGP glycosylation using monosaccharide 
composition alone may be limited. There was very little variation in the levels of 
fucose within the scope of the seven injury samples gathered, suggesting that 
fucose may not be affected by injury induced APR as opposed to 
hyperfucosylation seen in Gallacher’s study (2009), Anderson’s study (2002) 
and Fujimura (2008), and the levels of glucose within the three samples it was 
found in showed very little variance. While more variance was found within the 
levels of glucosamine, galactose and mannose, there is perhaps not enough 
evidence to identify specific injury types on their own. The evidence gathered 
here provides important information on the carbohydrates that make up the 
glycosylation patterns of the AGP molecule. However, it is much easier to 
determine individual injury types using the oligosaccharide analysis 
chromatographs gathered. Out of the seven injury types, the chromatographs 
produced by SH001 18/3 and GI001 7/6/10 were markedly different from the 
other five injury types, with these samples showing a rising curve as the 
analysis goes on within the HPAEC, these samples are the only samples which 
pass over the 15nC range. However, these samples do not show as many 
discrete, definite peaks when compared to the other five samples, which while 
they do not possess any peaks higher than 15nC, they do possess definite, 
distinguishable peaks. In addition to the obvious differences seen in SH001 
18/3 and GI001 7/6/10, LG001 12/9 produced the smallest chromatogram seen 
throughout the study, with very low peak elution and decreasing peak activity 
compared to the other samples, suggesting a dramatic decrease in the 
complexity of the glycoform and supporting the theory that the injury suffered by 
the volunteer has produced an individual effect on the glycosylation of their 
AGP. 
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The other four samples, EW001 20/3, SH002 7/6/10, WR001 11/16 and 
XX001 ?/?, produced chromatographs that were similar in shape overall but do 
possess subtle differences. Removing the unknown from consideration at this 
point, as it is the focus of Aim 3, it has been noted that EW001 20/3, SH002 
7/6/10, and WR001 11/16 (Graphs 16 and 17), all possess a similar shaped 
curve, with minor differences between the three. What is interesting to note, is 
that these samples also share a degree of homology in peak shape and 
retention time. It should be noted that EW001 20/3 possesses a much smaller 
peak height than the other two samples, and possesses a peak within the bi-
sialylated area that is not present within the other two samples. It should also be 
reported, that WR001 11/16 possesses the highest peak heights of the three 
samples, and these peaks were shown to have slightly earlier retention times 
than those within the other two samples. What is interesting to note is the 
homology that WR001 11/16 and SH002 7/6/10 share in particular; WR001 
11/16 is a wrist fracture injury, and it has been found since the project had 
finished that SH002 7/6/10 was a misdiagnosed shoulder fracture injury, this 
shows the potential of injury types to produce similar glycosylation patterns 
when considering one type of injury, i.e. fractures. Conversely, these samples 
may lead to the suggestion that perhaps that AGP glycosylation pattern 
alteration may be dependant not on the type of injury, but the area the injury 
has occurred in, due to the obvious similarities between the three samples 
regardless of the injury type, while all three injuries had taken place within the 
arm of these volunteers. However, the evidence in support of this theory is 
limited as there are two shoulder injury samples within this project, and neither 
of these samples bear any resemblance to each other, most probably due to 
these injuries being two different types of shoulder injury. 
 It has also been seen in Gallacher’s study (2009), that tested samples of 
the same degree of breast cancer from different volunteers have also produced 
slightly different oligosaccharide patterns, this was also found within Anderson’s 
study (2002) when considering multiple samples from the same types of liver 
diseases. This variability within sample groups was also found within Behan’s 
study (2010) when studying the glycosylation patterns within volunteers on 
different types of methadone recovery therapy. This evidence suggests that the 
oligosaccharide patterns may not be entirely reproducible, however, it has been 
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seen within this study that different injury types have the ability to produce 
different types of oligosaccharide patterns and the ability to produce similar (not 
exact) glycosylation patterns from similar injury types, with SH002 7/6/10 and 
WR001 11/16 representing this best. Due to the limited sample group for this 
project, the evidence of the reproducibility of glycosylation patterns between 
similar injury types from different volunteers may be limited.  In conclusion, the 
evidence presented in this section of the project suggests that different injury 
types have the potential to produce different effects on the glycosylation 
patterns of AGP, however, further research must be carried out in order to 
definitively confirm this theory. 
 Finally, the last aim of this project was to determine the diagnostic 
potential of glycosylation patterns of AGP, having presented evidence of an 
effect on the glycosylation patterns of AGP as a result of an APR induced by a 
physical injury, and that different injury types can produce different effects on 
AGP glycosylation. Thus, the final stage of the project was to determine 
whether or not there is any diagnostic potential in AGP glycosylation patterns 
when these glycosylation changes have been induced by an injury APR. The 
diagnostic potential of AGP glycosylation patterns has been seen before, with 
Gallacher’s study (2009) showing that glycosylation patterns of AGP can 
distinguish between different severities of breast cancer, Anderson (2002) 
showing the potential of AGP to diagnose different types of liver diseases; in 
addition to these advancements, altered fucosylation of AGP has also been 
shown potential to act as a biomarker during pregnancy development (Orczyk-
Pawilowicz et al., 2009). 
 The approach of this author to answering this question was to follow the 
same two fold analysis that was used for Aims 1 and 2 within this project. An 
unknown sample was collected from a project volunteer, the identity of the injury 
remained anonymous throughout the project so that this aim could possibly be 
determined without bias being a factor. This sample, XX001 ?/? (Graphs 6 and 
18), was collected and processed along with the other samples in the study, 
while the paperwork relating to the volunteer was kept in a sealed folder until  
analysis had been completed, after which, the sample’s injury type was 
revealed once. 
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 The following speculative discussion and conclusion as to the injury 
under question was made without any knowledge of the injury, which remained 
sealed until the author had drawn these conclusions. To determine the identity 
of the unknown sample, identification would be made on the basis of three 
comparisons; first, the monosaccharides present within the unknown were 
compared to those within the known injury samples, followed by a comparison 
in the amounts of monosaccharides detected. This was achieved by looking at 
the percentage change of monosaccharides detected within a known injury 
sample against the monosaccharides detected within the normal blood sample, 
and comparing it to the percentage change of monosaccharides detected within 
the unknown sample against the normal blood sample. The two main 
monosaccharides of interest within this comparison were that of fucose and 
galactose, due to their status as potential markers for the extent of glycosylation 
(Fournier et al., 2000, Anderson, 2002, Gallacher, 2009). The level of 
percentage change allowed to be considered for a match was +/- 5% in order to 
be significant. Finally, a visual comparison of the oligosaccharide trace gathered 
from the unknown was then carried out against the oligosaccharide traces from 
the known injury samples. 
 When comparing the monosaccharide composition’s of the tested 
samples, on a visual level the samples that were found to be the closest match 
to that of the unknown were SH002 7/6/10 and WR001 11/16 (see Table 9). In 
fact, when statistical analysis was carried out, it was seen that differences 
between SH001 18/3, GI001 7/6/10, EW001 20/3, and LG001 12/9 against the 
unknown injury sample were statistically significant. Furthermore, this was 
supported by a statistical comparison of SH002 7/6/10 and WR001 11/16 
against the unknown sample, where it was seen that these differences were not 
statistically significant, suggesting that it could be possible to match one of 
these two samples to the unknown sample. The unknown could match that of 
SH002 7/6/10, with there being no change in the levels of fucose, and 0.6% 
increase in the levels of galactose within the unknown sample when compared 
to the known injury sample. They both contain all the expected 
monosaccharides and the unexpected monosaccharide in glucose, however, 
the biggest difference between the two samples is that of their levels of 
mannose, with a 0.4µg difference in the level of mannose between the samples. 
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As a result of this difference, it could then be argued that the unknown sample 
is that of WR001 11/16 also; the levels of fucose and galactose within WR001 
11/16 also fall within the 5% range, with there being a 2.9% increase in fucose 
and 3.6% decrease in galactose within the unknown injury sample when 
compared against the respective levels within the known injury sample. Again, 
the two samples share the presence of all of the expected monosaccharides 
and glucose, however, there is also a 185.7% increase in the level of 
glucosamine within the unknown compared to the known injury sample.  As a 
result of these similarities, theories as to the identity of the unknown sample 
were able to form, however, it was not possible to make a conclusive diagnosis 
based on this information; as such the oligosaccharide structure of the unknown 
was then compared to the oligosaccharide results gathered from the other 
tested samples within the project. 
 When considering the oligosaccharide structures of the tested samples 
of the project, it was quick to remove SH001 18/3 and GI001 7/6/10 from 
consideration due to the large differences from the unknown sample within 
them. It was found in a study by Brinkmann-van der Linden et al., (1996) that 
acute inflammation states would produce an increase in bi-sialylated glycans, 
however, four out of the seven samples tested, would show an increase in more 
complicated branching types. Gallacher’s work in (2009) would also support this 
theory due to the increased presence of bi-sialylated glycans in invasive breast 
cancer samples, however, Anderson’s (2002) when studying liver diseases 
found that as the liver disease severity increased, the branching complexity 
would see a shift from bi-sialylated branches to tri- and tetra-sialylated branches 
(particularly, when hepatitis C infections progressed from acute to chronic). 
LG001 12/9 was removed from consideration due to the vast differences it 
possessed against the unknown. EW001 20/3 does share some similarities with 
the unknown, with a degree of homology between the unknown and EW001 
20/3 in terms of peak complexity and retention time, which while not exact, 
there are definite similarities between the two samples. However, EW001 20/3 
possesses a prominent peak within the bi-sialylated area of the chromatograph, 
along with a marginally different peak elution from the unknown. When 
considered along with the monosaccharide results (EW001 20/3’s levels of 
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fucose and glucose fall outside the allowed 5% range), it may be unlikely that 
the unknown is that of EW001 20/3, an elbow injury.  
 This then leads to the consideration of SH002 7/6/10 and WR001 11/16 
(see Graphs 13 and 31). When comparing SH002 7/6/10 and the unknown 
sample, there is very little that can separate the two samples. The two samples 
possess a large degree of homology in terms of peak complexity and peak 
retention time, with the biggest difference between the two samples being that 
of peak height; the unknown possessing larger peak heights than that of SH002 
7/6/10, however, the two chromatograms could be placed upon one another. 
When considered with monosaccharide results, where the biggest difference is 
still the difference in the levels of mannose, there is strong evidence that SH002 
7/6/10 could be the same injury type as the unknown sample.  
 When considering WR001 11/16 and the unknown sample, again there is 
very little that can separate the two samples. The two samples share a large 
degree of peak complexity, and WR001 11/16 possesses a closer peak elution 
to the unknown than that of SH002 7/6/10. However, the peaks within WR001 
11/16 have came off slightly earlier than those within the unknown sample. 
Again, the biggest difference when considering monosaccharide analysis is the 
levels of glucosamine between WR001 11/16 and the unknown sample.  
 As such there are two samples of which could be related to the unknown 
sample, SH002 7/6/10 and WR001 11/16. There is very little that can separate 
these two samples from being homologous to that of the unknown sample. 
When the sealed folder containing the volunteer’s unknown paperwork was 
opened, it was found that the injury suffered by the volunteer was that of an 
elbow fracture. As a result of this injury, the evidence provided by the unknown 
sample supports two theories proposed by this study. Firstly, the revelation of 
the unknown being that of an elbow fracture, while producing similar 
oligosaccharide chromatographs and being of similar monosaccharide 
compositions to the wrist fracture seen in WR001 11/16, and seen in SH002 
7/6/10, when it was subsequently seen to be a shoulder fracture, supports the 
theory that injury induced alterations of AGP glycosylation patterns can produce 
changes within the carbohydrate of the AGP molecule that are injury specific. 
Secondly, as a result of this information, the revelation of the unknown injury 
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type through the comparison of monosaccharide composition and 
oligosaccharide structure of other injury samples shows the diagnostic potential 
of changes to AGP glycosylation patterns when induced by injury. It should also 
be noted the similarities that the unknown shares with EW001 20/3 could 
perhaps suggest that EW001 20/3 (an abrasion injury to the elbow) could 
perhaps have been a more serious injury than first thought due to the 
similarities that EW001 20/3 shares with the known fracture injuries within this 
study. However, the medical potential of this evidence is limited due to the small 
scope of this project. 
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5. Conclusions 
 In conclusion, there were three aims in this project. These were to 
determine whether or not AGP glycosylation patterns could be altered as a 
result of an injury induced APR process, and if so, could different injury types 
produce different changes to the glycosylation patterns of AGP? Finally, is there 
any diagnostic potential within the glycosylation patterns of AGP when altered 
by physical injury? 
 As it formed the basis of the entire project and any potential future work 
within this area, the biggest aim was to determine whether or not physical 
injuries can in fact alter the glycosylation patterns of AGP. Through the 
monosaccharide composition and oligosaccharide structural analysis of the 
gathered seven injury samples and the four normal samples, a carbohydrate 
fingerprint was constructed for each sample, which would then allow 
comparisons and similarities between each sample to be drawn. When the 
injury samples had been analysed and compared to the normal blood sample 
there was evidence within the injury samples that a change had taken place.  
As seen throughout the project, the level of differences between the 
injured samples and the normal blood sample was minute in the µg level, 
however, changes were observed and quantified. The research within this 
project adds to what is already known about AGP, by showing that injury 
induced APR does have an effect on the glycosylation patterns of AGP. Within 
the scope of this project, each injury was shown to affect the glycosylation 
pattern of the volunteers AGP through the comparison of injury AGP samples 
against a normal blood sample, and subsequently in some cases, a healed 
blood sample from the same volunteer. While obvious differences were 
observed between the injury AGP samples and the normal blood sample, there 
were more subtle difference observed within comparisons of injury AGP 
samples and healed injury samples from the same volunteer. However, while 
more subtle differences were observed within these comparisons, the 
information gathered was invaluable as it allowed the observation of a before 
and after state of an individuals injury, while at the same time showing the 
differences that can occur between individuals with different injuries.  
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Furthermore, when it was confirmed that different injuries can produce 
different effects on the glycosylation patterns on an individuals AGP, it was the 
aim of this project to determine whether or not there was any diagnostic 
potential in AGP glycosylation patterns. When the unknown sample was 
compared against the evidence collected from the known injury samples, it was 
found that the unknown sample shared a great deal of homology at the 
monosaccharide and oligosaccharide levels with the known wrist fracture and 
shoulder break within the project, leading to the theory that changes to the 
glycosylation patterns of AGP were dependant on the injury received with no 
regards to where the injury had taken place. This theory was then strengthened 
when the unknown injury sample was revealed to be an elbow fracture, thus 
showing that there is diagnostic potential within the glycosylation patterns of 
AGP that have been affected by injury induced APR.  
In conclusion, the main aim of the project was to determine whether or 
not physical injury induced APR can produce changes in the glycosylation 
patterns of AGP, akin to those changes seen to have taken place within 
different severities of breast cancer and different types of liver diseases. 
Through the monosaccharide and oligosaccharide analysis of the gathered 
injury samples and their comparisons against the normal samples, it has been 
determined that injury induced APR does produce an effect on the glycosylation 
patterns on AGP within those injured individuals. It is possible to categorize this 
change both qualitatively and quantitatively. Furthermore, it has been 
determined that there is diagnostic potential within the glycosylation patterns of 
AGP with regards to injury induced APR. This information can then be used as 
the basis for further research into the effects of injury induced APR changes on 
AGP glycosylation patterns.  
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6. Further Research 
 
As a result of the conclusions reached within this project, should further 
research into the effects of injuries on glycosylation patterns, then further 
research recommendations are; 
 Increase the sample size for further project research; within this 
project, seven injury samples from volunteers were gathered, four 
healed reference samples were gathered from previous 
volunteers, along with a normal blood sample, monomix solutions 
and an N-Lib. Should time allow, a larger sample group would be 
ideal, as would an increased sample type range (with nearly half 
of these project samples containing fracture/break injuries) would 
also be beneficial.  
 If the acquirement for more and different sample types is possible, 
then the development of a “glycosylation pattern database for 
injury types” would allow for the storage of reference information 
relating to the glycosylation patterns of specific injuries. This 
would then allow further research into the diagnostic potential of 
the glycosylation patterns of AGP, with the comparisons of newer 
unknown injury types against the known injury types within the 
database. 
  Should more research be carried out within this area, a further 
recommendation would be to analyze a persons glycosylation 
patterns over the course of their recovery, to determine how the 
glycosylation patterns of AGP behave throughout the recovery 
process, so that it may be possible to develop a biomarker to 
show a persons recovery from a physical injury. Could 
glycosylation patterns of AGP be useful to track a person’s 
recovery from overuse/over training injuries?  
 Finally, should it be possible to develop a biomarker for the 
recovery from physical injury, then would there be potential to 
chart the effectiveness of different therapies for more serious 
injuries, i.e. which is a more effective treatment for a torn bicep, 
surgery or physiotherapy? 
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Appendix 
Appendix 1 Volunteer Information Sheet 
Alpha-1 acid glycoprotein (AGP) as a serum biomarker for sport injury 
 
We would like volunteers to take part in a Research Study funded by Edinburgh Napier 
University. The study is designed to examine the structural changes that occur to Alpha-1-acid 
Glycoprotein (AGP) under the stresses of a physical sporting injury and to determine if AGP can 
be used to diagnose and chart the recovery of the individual from their injury. 
 
Why have I been chosen? 
Inclusion in this project will be based on the severity of the injury to the individual. All 
ages and gender of rider will be considered, however, those under the age of 18 will have to 
obtain written consent from their parents before inclusion in the project. 
 
 What will happen to me if I take part? 
We would like to collect one 5ml sample (about three teaspoonfuls) of blood from 
you. The blood sample which is collected from you will have your name and address removed 
so that you cannot be recognised during the course of the research.  There will also be no 
transfer of any identical information about you nor will your medical record be accessed. 
You are free to withdraw from participation in the study at any point without 
explanation.  If, at all possible, your blood sample, and all associated data, will be removed 
from the study and destroyed. 
Should you have any enquiries into the project or would like to take part, please take 
one of the tags below and email me regarding your interest. 
Thank you for taking the time to read this leaflet. Your help is very much appreciated. 
 
William Surradge, Edinburgh Napier University, Sighthill Campus 
Email: 06017014@live.napier.ac.uk 
 
This study has been reviewed, and approved, by Faculty of Health, Life and Social Sciences 
Ethics and Governance Committee. 
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Appendix 2 Venepuncture Consent Form 
 
Subject Declaration for Vene Puncture Blood Donation 
You have consented to donate blood in the School of Life Sciences. The School 
phlebotomists have all undergone an approved training course and have Hepatitis B 
immunity. The blood you are donating will be used for                                         
………………………………………………………………………………………….but will 
not be screened for pathogenic organisms that could adversely affect the health of any 
exposed person. It is therefore important that you do not donate blood if any of the risk 
factors listed below apply to you. At the end of the experiment the cells will be disposed 
of and not stored for future experiments. 
Please read the list below and think very carefully if any apply to you. If any factors do 
apply please do not sign the declaration and do not offer your services as a donor. You 
do not have to say which risk factors apply. 
Risk Factors 
Recent –  
Ill-Health 
Contact with infectious diseases 
Vaccinations or immunisations 
In the last year- 
Tattoo or body piercing 
Childbirth 
Blood transfusion 
Tissue or skin graft 
Hormone treatment 
Major surgery 
Travel to a malarial area or in sub Saharan Africa, Asia or South America 
At any time – 
If you have lifestyle factors which would pose a risk please do not donate blood. 
Declaration 
I have read the risk factors and have considered my lifestyle factors and to the best of 
my knowledge none of them apply to me and I am in good health. I understand that my 
blood will be used for research purposes. 
Name of Donor: ........................................  Name of Phlebotomist: .........................................  
Signature of Donor: ...................................  Signature of Phlebotomist: ....................................  
Date: .........................................................  Date:.....................................................................  
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Appendix 3 Patient Questionnaire 
Patient Information Questionnaire  
Adapted from Stuart Aitken (details below) 
 
Glentress Mountain Biking Injury Study 
July 2007 – Jun 2008 
Stuart Aitken 
Orthopaedic Research Fellow, Royal Infirmary Edinburgh 
PLEASE CIRCLE THE MOST APPROPRIATE ANSWERS, OR SIMPLY WRITE IN THE 
SPACES PROVIDED. 
 
Name 
________________________________________________________________ 
 
Age & Gender 
_________________________________________________________ 
 
Postcode & Town 
______________________________________________________ 
 
 
Do you wear a helmet when you ride? Always Usually Sometimes Never 
Is it XC, Skater-style or Full-face? 
 
Do you wear gloves or mitts? Always Usually Sometimes Never 
 
Do you wear any other protective gear? Always Usually Sometimes Never 
If so, what kind of gear? 
 
What kind of pedal system do you use? SPDs or Cleats Flats Toe cages 
 
Which runs do you use most often? (Please circle). 
 
GREEN Every time Usually Seldom Never 
 
BLUE Every time Usually Seldom Never 
 
RED Every time Usually Seldom Never 
 
BLACK Every time Usually Seldom Never 
 
FREERIDE Every time Usually Seldom Never 
 
What kind of bike do you use? 
BMX Rigid frame Hardtail Full Suspension Other 
 
 
How many months / years experience of trail riding do you have? 
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What was the injury that you suffered while you were mountain biking? 
 
________________________________________________________ 
 
Did the injury require an extended hospital stay? (This is anything longer 
than an overnight stay.) 
 
________________________________________________________ 
 
How long has it been since the injury occurred (till the time of the provision 
of the blood sample)? 
________________________________________________________ 
 
What is the projected recovery time for this injury? 
 
________________________________________________________ 
 
 
How many times in the last 12 months have you had to go to Hospital with a 
Mountain biking injury?  
________________________________________________________ 
 
